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When cultured in vitro, human embryonic stem cells (hESCs) 
acquire genetic abnormalities that have slowed their therapeutic 
use. As hESCs have a “leaky” G1/S boundary, the pressure of 
ensuring genetic integrity falls on the G2/M checkpoint, which 
can be activated by failed chromosomal decatenation (among other 
stimuli). It is hypothesized that hESCs have a deficient 
decatenation checkpoint, but little data supports this. Evidence 
suggests that the ataxia telangiectasia mutated (ATM) kinase 
controls the G2/M decatenation and DNA damage checkpoints, 
though previous reports are conflicting on this point. My work 
demonstrates that inhibition of decatenation activates ATM and 
arrests hESCs in G2. Pharmacologic inhibition of ATM (ATMi) 
abrogates this arrest, allowing hESCs to enter mitosis. Live 
cell imaging studies reveal that ATMi increases the time it 
takes to complete mitosis. Culture of cells under ATMi causes a 
gain of DNA content, which is reversed once ATMi is relieved. 
BRCA1, a known target of ATM, is also involved in the G2/M 
checkpoint. Experimental evidence reveals that activated ATM 
phosphorylates BRCA1, preventing Aurora A from interacting with 
and phosphorylating BRCA1 on S308, a modification necessary for 
mitotic entry. Together, this data illuminates a novel pathway 
by which ATM activation mediates G2 arrest in hESCs. 
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Chapter 1:  
Introduction to Embryonic Stem Cells 
 
“Progress in basic developmental is now extremely rapid; human 
embryonic stem cells will link this progress even more closely 
to the prevention and treatment of human disease.” 
- James A. Thomson 
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Embryonic stem (ES) cells, derived from the inner cell mass 
(ICM) of a pre-implantation blastocyst, promise advances in 
developmental biology, drug discovery, and regenerative medicine 
that other cell lines cannot. Proposed breakthroughs come from 
the stem cell’s defining property: pluripotency, or the ability 
to differentiate and form all three germ layers of the human 
body – the endoderm, mesoderm, and ectoderm (Figure 1.1). This 
differentiation down specific lineages takes place through 
symmetric or asymmetric division. Symmetric division generates a 
virtually unlimited supply of pluripotent cells, whereas 
asymmetric division produces one pluripotent cell and one 
differentiated cell. ES cells, first isolated from standard 
laboratory animals and later, from humans, have been a source of 
much controversy and debate. While their scientific potential is 
widely acknowledged, practical therapies have yet to develop. 
Though politics and public opinion have played a part, there are 
significant hurdles to overcome in the laboratory before novel 
treatments can be brought to the clinic.  
 
Much of the work done on human embryonic stem cells (hESCs) has 
been based on studies done in mouse embryonic stem cells 
(mESCs). For years, the major method for isolating cells from 
the ICM of mouse blastocysts involved complicated and time-
consuming microsurgical methods. In 1975, Solter and Knowles, 
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interested in studying the immunological maternal-embryonic 
relationship, discovered a method for large-scale collection of 
cells from the ICM. They isolated blastocysts by flushing them 
from the uterine horns on the fourth day of pregnancy, 
chemically removing the zonae pellucidae, exposing the 
blastocysts to specialized anti-serum and complement, then 
removing the damaged trophoblastic layer by pipetting the 
blastocysts through a small-bore glass pipette (Solter and 
Knowles, 1975). After isolating the ICM, they plated the cells 
and described their appearance as such: 
 
“Inner cell masses plated in plastic dishes developed along two 
morphological routes: approximately half attached to the surface 
and from them relatively large polygonal cells with small 
vacuoles began to grow. Outgrowth of trophoblastic cells was 
never observed. The central mass of cells then either continued 
to grow as a solid mass and eventually developed into a 
structure resembling a 7-day-old mouse embryo, or it spread and 
formed a monolayer composed of several cell types. Half of the 
inner cell masses did not attach but continued to grow, floating 
in the medium, forming embryoid bodies with a clearly visible 
outer cell layer and a solid mass of cells inside.” 
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These descriptions are characteristic of pluripotent stem cells, 
though no such statements were made. The authors conclude their 
study by asserting that their technique is an effective method 
for the isolation of large numbers of ICM’s (Solter and Knowles, 
1975), thus setting the stage for future work in stem cell 
research. However, it would still be several years before 
pluripotent cells would be successfully propagated in vitro. 
 
The first report of establishing a line of pluripotent cells 
from mouse blastocysts was published in 1981 (Evans and Kaufman, 
1981). There had been several previous attempts to establish a 
stable cell line (Atienza-Samols and Sherman, 1978; Cole and 
Paul, 2008; Sherman, 1975; Solter and Knowles, 1975), but none 
were successful. It was hypothesized that sustained, successful 
culture of pluripotent cells would depend on three factors: 1) 
pluripotent cells exist in an embryo which could be propagated 
in vitro, 2) it is possible to harvest these cells from the 
embryo, and 3) tissue culture conditions could be developed to 
encourage expansion, not differentiation of pluripotent cells 
(Evans and Kaufman, 1981). To support their hypothesis, 
researchers harvested blastocysts from mice and cultured them in 
groups of approximately six embryos for four days. The 
blastocysts attached to the dish within 48 hours, and the ICM 
developed into “large egg cylinder-like structures”, which were 
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picked, dispersed with trypsin, and passaged onto Petri dishes 
coated with mitomycin C-inactivated STO fibroblasts (Evans and 
Kaufman, 1981). The isolated and expanded cells were found to 
have a normal karyotype and key traits of pluripotent cells, and 
were able to survive ~30 passages (at the time of publication) 
(Evans and Kaufman, 1981). The successful acquisition and 
expansion of a stable mESC line set the stage for over two 
decades of work before the first non-human primate embryonic 
stem cells were derived.  
 
While the isolation and ex vivo expansion of mESCs represented a 
major step forward and catalyzed an avalanche of groundbreaking 
research, there are enough differences between human and mouse 
embryonic development that scientists wondered if the 
conclusions drawn from mESC research would accurately reflect 
the processes that occurs in humans. After all, the overall goal 
was (and is) to use this type of cell in regenerative medicine. 
If novel therapies were to develop, then a more appropriate 
model needed to be established. To that end, James Thomson, 
working out of the University of Wisconsin, set out to create 
embryonic stem cells using an organism which more closely 
resembled a human: the rhesus monkey. Using the 
antiserum/complement technique developed twenty years before 
(Solter and Knowles, 1975), Thomson and colleagues successfully 
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isolated and expanded primate embryonic stem cells (Thomson et 
al., 1995). As hypothesized, there were several major 
differences between these cells and mESCs (see Table 1.1 for a 
summary of these differences). The differences in the 
fundamental biology of stem cells were significant enough that 
the authors concluded that for embryonic stem cells to have a 
future in regenerative medicine, primate or, ideally, human 
embryonic stem cells would need to be used (Thomson et al., 
1995). In fact, the year before had seen a paper published where 
ICM-derived cells from spare in vitro fertilization human 
embryos were isolated and cultured. However, while pluripotent 
cells were detected, they did not survive beyond two passages 
(Bongso et al., 1994). It was clear that the field of embryonic 
stem cell research was moving into humans, and it would be the 
Thomson group that would eventually take it there. 
 
The first description of the isolation and culture of hESCs was 
published in 1998. Thomson and his colleagues collected fresh or 
frozen cleavage stage embryos which were produced by in vitro 
fertilization for clinical purposes (Thomson et al., 1998). 
Importantly, they achieved informed consent from both the donors 
and their University’s Institutional Review Board. Using the 
same technique which was developed to isolate pluripotent cells 
from rhesus monkeys, Thomson’s group ultimately isolated 14  
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human ICMs and derived from five embryonic stem cell lines 
originating from five separate embryos. Importantly, these newly 
derived hESCs expressed high levels of telomerase, the enzyme 
responsible for producing telomeres (Thomson et al., 1998). 
Telomeres are short, repetitive stretches of DNA composed of the 
nucleotide sequence TTAGGG, which function to preserve the 
structural integrity of each chromosomal end (Hall and Giaccia, 
2012). Telomeres act as a “capping mechanism”, ensuring that the 
ends of each chromosome are not inappropriately chewed back by 
exonucleases, thus distinguishing the ends from double-strand 
breaks (which the cell would attempt to repair) (Lundblad, 
2000). As somatic cells divide, each successive division results 
in marginally shortened telomeres. Once the telomeres reach a 
critical length, growth stops and cells either become senescent 
or die (Hall and Giaccia, 2012). The expression of telomerase in 
hESCs effectively renders them immortal, adding to their allure 
for use in medical research. These newly described hESCs were 
remarkably similar to the primate embryonic stem cells, and 
showed similar contrasts to mESCs (see Table 1.1)(Thomson et 
al., 1998). The successful creation of hESC lines promised rapid 
advancement for our understanding of a variety of diseases, 
however, a myriad of ethical and political controversies would 
surround these cells and significantly limit their use for the 
next decade. 
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The controversy over public funding for embryonic research 
 
The ethical debate over the use of human reproductive tissues 
for medical research has been ongoing since the late 1970s, when 
it became clear that biomedical science was entering an era 
where these tissues could, and would, be used routinely in the 
laboratory setting (Gottweis, 2010). This debate eventually 
resulted in an outright ban on government support for any form 
of fetal research from 1988-1993 (Wertz, 2002). However, private 
funding was still allowed, creating an odd environment in which 
controversial research could take place, virtually unregulated 
in the private sector, but publically funded research was 
effectively rendered illegal. This ban was lifted by President 
Clinton in 1993, which resulted in the National Institutes of 
Health (NIH) forming the Human Embryo Research Panel (HERP), a 
division responsible for creating guidelines mandating 
appropriate and inappropriate areas of embryonic research 
(Tauer, 1997). While HERP decided that it was acceptable to 
conduct research on “leftover” embryos from in vitro 
fertilization, Congress, via the Department of Health and Human 
Services appropriations process, decreed that “any activity 
involving the creation of, destruction of, or exposure to risk 
of injury or death to human embryos for research purposes may 
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not be supported with federal funds” (Gottweis, 2010). While 
public funds were now freed up to sponsor stem cell research, 
support was still coming solely from the private sector until 
the end of 1999, chiefly from the Geron Corporation and Advanced 
Cell Technology (Annas et al., 1999). In late 2000, the NIH 
published guidelines for stem cell research, and almost a year 
later, President Bush laid out a governmental policy which 
permitted public funding for hESC research using only pre-
existing cell lines (which were derived using private funds) 
(stemcells.nih.gov/policy/pages/2001policy.aspx). In early 2009, 
President Obama significantly expanded the scope of cell lines 
which could be supported by public funds with the Executive 
order “Removing Barriers to Responsible Scientific Research 
Involving Human Stem Cells” 
(stemcells.nih.gov/policy/pages/2009guidelines.aspx). The 
effectiveness of this expansion was short lived, however, when a 
U.S. district court issued a preliminary injunction banning the 
use of federal funding for hESC research in 2010. This ruling 
was temporarily put on hold by the U.S. Court of Appeals, and it 
was eventually overturned in 2011 
(stemcells.nih.gov/staticresources/Sherley_Mem_Op_granting-Defs-
Mot-Summ-J.pdf). While hESC research has currently been allowed 
to continue, a more comprehensive and cohesive policy is clearly 
needed to streamline the process of hESC research in the U.S.  
12 
 
Induced Pluripotent Cells: A Novel Compromise 
 
hESC research presents an interesting quandary – on one hand, 
the cells present an almost limitless opportunity for scientific 
advancement. On the other hand, the major legal and ethical 
controversies surrounding them have significantly limited 
progress towards any biomedical breakthroughs. To this end, 
researchers have been attempting to find a work-around for 
creating pluripotent cells from sources other than human 
embryos. This has two major advantages: 1) the use of human 
embryos can be avoided and 2) potential histo-compatibility 
problems can be solved (e.g. “growing” a new pancreas for a 
diabetic patient, only to have it rejected because the ES cells 
used had the wrong antigenic markers).  
 
Investigators have been experimenting with cellular 
reprogramming for decades. The first success came in 1952 when 
researchers demonstrated that taking nuclei from blastula-stage 
embryos and transplanting them into enucleated frog eggs 
resulted in normal, hatched tadpoles (Briggs and King, 1952). 
This “nuclear transfer” method would be used extensively and 
eventually result in the successful somatic cloning of many 
different species (the most notable of which was “Dolly” the 
sheep) (Wilmut et al., 1997). However, this technique is still 
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limited in humans by the requirement for oocytes, thus not 
completely circumventing the issue of the use of reproductive 
tissues. 
 
Another method for cellular reprogramming is the fusion of ES 
cells with differentiated cells, somehow forcing the somatic 
cells back through to a pluripotent stage. This process has been 
demonstrated in both mice (Tada et al., 2001) and humans (Cowan 
et al., 2005). However, the molecular mechanisms behind this 
process are not fully understood, and it has not yet been 
clarified if these fusion-transformed cells are 100% pluripotent 
(Yamanaka, 2007). 
 
An interesting (if little studied) method developed for this 
process is spontaneous reprogramming by culture. For example, it 
has been shown that long-term culture of bone marrow-derived 
cells can induce pluripotency (Jiang et al., 2002), as well as 
the prolonged culture of germline stem cells from mouse testes 
(Kanatsu-Shinohara et al., 2004). Strongly limiting this 
technique is supporting evidence for the generality, 
reproducibility, and yield of pluripotent cells. Additionally, 
relying on long-term culture to produce pluripotent cells in any 
quantity sufficient enough for regenerative medicine is a 
prohibitive barrier.  
14 
 
 
The most recent, and most promising, development for the 
creation of reprogrammed somatic cells is the four-factor 
transformation method developed by Takahashi and Yamanaka in 
2006. These de-differentiated cells were termed induced 
pluripotent stem (iPS) cells. Yamanaka’s group identified 
twenty-four transcription factors which, when transduced into 
mouse fibroblasts, resulted in the creation of (albeit rarely) 
colonies of pluripotent cells. Through trial-and-error they 
narrowed down the twenty-four transcription factors into four: 
Oct3/4, Sox2, Klf4, and c-Myc (Takahashi and Yamanaka, 2006). 
The next year, both Yamanaka and another laboratory used the 
same technique to create human iPS cells (Takahashi et al., 
2007; Yu et al., 2007). 
 
In his 2007 review, Shinya Yamanaka proposed a model by which 
these four key transcription factors work together to promote 
pluripotency. c-Myc overexpression, in isolation, can cause p53-
dependent apoptosis in primary cells. However, KLF4 expression 
can suppress p53, thereby preventing cell death. On the other 
hand, KLF4 can activate p21, which suppresses cell 
proliferation, and c-Myc in turn suppresses p21. The cell needs 
to strike a balance between the expression and interaction 
between c-Myc and KLF4 in order to remain viable. Additionally, 
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c-Myc can “loosen” the chromatin architecture, potentially 
opening up promoters for other genes/proteins important in 
pluripotency (Meshorer et al., 2006). However, just expressing 
c-Myc and KLF4 would direct cells towards a cancerous fate, not 
an embryonic stem cell phenotype. Oct-3/4 and Sox2 likely come 
into play here, activating multiple genes important for 
pluripotency (and not malignancy). Yamanaka hypothesizes that 
the c-Myc-mediated opening of chromatin facilitates Oct-3/4’s 
and Sox2’s ability to activate the appropriate genes (Yamanaka, 
2007). The balance of factors required for pluripotency appears 
both elegant and delicate, and much work remains to be done in 
this area to enhance our understanding. 
 
Since this groundbreaking work, several other methods have been 
developed based around the four key transcription factors. This 
work was spurred on by concern over Yamanaka’s use of retroviral 
transduction, causing permanent genomic alteration. The 
retroviral integration can lead to tumor development, as well as 
continued expression of pluripotent factors in cells derived 
from iPS cells (Yu et al., 2009). The first modified 
transformation protocol involved using non-integrating 
adenoviruses transiently expressing the four key pluripotency 
factors (Stadtfeld et al., 2008). Later, a separate group 
demonstrated successful transformation using purified 
16 
 
recombinant proteins (though this work was done in mice) (Zhou 
et al., 2009). Along these same lines, a third group achieved 
de-differentiation using synthetic mRNA, which was modified to 
overcome innate cellular antiviral responses (Warren et al., 
2010). These so-called “RNA-induced pluripotent stem cells” were 
able to be efficiently directed down a new lineage, 
differentiating into myogenic cells (Warren et al., 2010). 
Though still in its infancy, this work promises to bring the 
advantages of iPS cells without the limitations of using 
integrating retroviruses. 
 
iPS cells hold several advantages over hESCs, beyond the ethical 
and immunogenicity factors. One of the most promising uses of 
these cells is in disease modeling. There have been several 
papers published describing the reprogramming of diseased cells 
in order to gain a greater understanding of their underlying 
biochemistry (see (Cherry and Daley, 2012) and (Park et al., 
2008) for example). The use of iPS cells is exciting because one 
could theoretically create cells from both diseased and healthy 
individuals (within the same family), leading to the study of 
genetic variants that could both positively and negatively 
affect the development of diseases, as well as disease outcomes 
(Ferreira and Mostajo-Radji, 2013). The most interesting 
demonstration of the power of iPS cells came out of Rudolf 
17 
 
Jaenisch’s lab in 2007. Jaenisch’s group, using a mouse model of 
sickle-cell anemia, first harvested fibroblasts which contained 
the mutant hemoglobin gene. They then transformed the 
fibroblasts into iPS cells, corrected the mutation, 
differentiated the cells into blood progenitors, ablated the 
bone marrow in experimental mice, and transplanted the corrected 
progenitors into the sickle-cell mice. This process resulted in 
a lasting cure for the diseased mice (Hanna et al., 2007). 
Techniques such as this could be adapted and improved, providing 
similar therapies for human patients. 
 
As with any new technology, there are several limitations to 
adapting iPS cells for therapeutic use. Yamanaka’s original 
paper complains of the ultra-low frequency of transformation 
(Takahashi and Yamanaka, 2006), which could present a barrier to 
growing a large enough population for use in regenerative 
medicine. As mentioned earlier, some of the techniques for 
creating pluripotent cells involve the use of integrating 
retroviruses, which have tumorigenic potential. This potential 
is expounded upon when one of the transduced factors is c-Myc, a 
commonly overexpressed oncogene. Interestingly, c-Myc can be 
removed and pluripotency achieved with only the three other 
factors, but this technique is significantly slower (Wernig et 
al., 2008). One study also reported that transplanted autologous 
18 
 
iPS cells could induce a T cell-mediated immune response, where 
autologous ES cells could not (Zhao et al., 2011). Finally, 
human iPS cells have been found to frequently develop 
chromosomal aberrations, which could be attributed to 
adaptations to prolonged culturing (Mayshar et al., 2010). The 
acquisition of aneuploidy, and genomic instability in general, 
haunts traditionally derived ES cells as well. These unwanted 
genetic alterations have significantly affected efforts to bring 
pluripotent cells out of the lab and into the clinic.  
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Genomic Instability: An Unfortunate Hallmark of Pluripotency 
 
The first reports of hESC studies reported a diploid, normal 
karyotype (Amit et al., 2000; Reubinoff et al., 2000; Thomson et 
al., 1998). However, it was quickly discovered that prolonged ex 
vivo culturing and expansion of ICM-derived cells caused them to 
become aneuploid (Draper et al., 2004). There are several 
theories as to how cells become aneuploid; however, the 
breakage-fusion-bridge model is the most widely accepted (see 
Figure 1.2). In this model, cells either experience an 
unrepaired double-strand break (DSB) or a telomere is degraded 
enough that it is sufficiently similar to a DSB. This lesion is 
duplicated during S-phase and the two broken chromosomes fuse, 
or the cell is unlucky enough to have a separate chromosome that 
also has an exposed end. In either case, the broken chromosomes 
fuse, creating a chromosome with at least two centromeres 
(termed a “dicentric” chromosome). Additionally, there can be a 
failed attempt at homologous recombination between two non-
homologous chromosomes which then become stuck together. 
Whatever the cause, when these multi-centric (“bridged”) 
chromosomes enter mitosis, they are ripped apart during 
anapahase (“breakage”), once again  leaving an exposed end that 
can fuse with another chromosome. This cycle is then repeated 
(for a more extensive review, see (Morgan, 2007)). 
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Normally, cells that experience such chromosomal aberrations 
will die. However, certain structural changes (and a gain or 
loss of certain genes) can provide a growth advantage, causing 
the mutant cell to eventually overtake the in vitro population 
(or, in the case of an organism, cause tumor formation). 
Unfortunately, evidence suggests that both hES and iPS cells are 
prone to genetic abnormalities almost from the beginning. In the 
case of pre-implantation stage embryos, it has been estimated 
that as many as 30-65% of cells are already aneuploid (Wilton, 
2002). In a recent study, it was found that certain lines of iPS 
cells became aneuploid shortly after pluripotency was 
established (while the parental cells were determined to be 
euploid) (Kim et al., 2009). 
 
While pluripotent cells can be aneuploid from the start, it is 
far more common for them to develop abnormalities when cultured 
for a long time. This has been most extensively studied in 
hESCs. In 2004, a collaborative paper was published (between the 
University of Sheffield and the University of Wisconsin) 
describing hESCs which eventually (and independently) developed 
trisomy of chromosomes 12 and 17 (Draper et al., 2004). There 
are several competing (or complementary) theories as to how 
prolonged culture can promote the development of aneuploidy 
(reviewed extensively in (Baker et al., 2007)). First, and most 
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importantly, the technique each lab uses to culture pluripotent 
cells can have a major impact on whether or not genomic 
instability occurs. One study found that cells passaged using 
manual dissection (selecting and transferring colonies by 
deliberate choice) were able to maintain euploid karyotypes 
after ~105 passages, whereas bulk passaging methods (trypsin, 
collagenase, etc.) witnessed the development of aneuploidy after 
23-45 passages (Mitalipova et al., 2005). However, since that 
study was published, methods have been developed to preserve a 
normal karyotype while bulk-passaging ES cells using enzymatic 
techniques (Suemori et al., 2006). Another theory of aneuploid 
development is the different oxygen tensions pluripotent cells 
experience in vitro vs. their in vivo environment.  Cells in 
culture are kept at a significantly higher oxygen tension than 
what they would experience in the body, and this, in turn, has 
significant effects on development (see (Harvey, 2007), for 
example). High oxygen tension has been found to cause damage in 
both nuclear and mitochondrial DNA (von Zglinicki et al., 2000), 
and studies in hESCs have found mutations in mitochondrial DNA 
after prolonged culture under high oxygen conditions (Maitra et 
al., 2005), supporting the notion that oxygen levels influence 
genomic stability. 
 
Finally, there are several additional factors which may 
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influence survival and karyotype preservation, but these factors 
are difficult to dissect out and directly study. hESCs are 
widely disseminated through large cell banks; the freeze-thaw 
cycles which these cells undergo may inadvertently select for 
abnormal cells which can withstand these processes best. The 
method of culture (beyond the question of passaging) may also 
select for abnormal cells with a growth advantage. Laboratories 
have (for the most part) transitioned from using inactivated MEF 
feeder layers and homemade media to artificial substrates 
(Matrigel) with defined, proprietary media (i.e. mTeSR-1 and-2 
from Stem Cell Technologies, or StemLine from Sigma-Aldrich). 
These newer, xenobiotic-free and extensively studied ingredients 
may help alleviate the problems associated with the originally 
developed methods. 
 
Pluripotent stem cells, both ICM-derived and artificially 
induced, harbor exceptional potential for developing therapeutic 
advances for many diseases. However, use of these cells has been 
hampered through legal and ethical quandaries, as well as the 
common acquisition of genetic abnormalities (e.g., aneuploidy) 
when expanded in the laboratory. As these abnormalities can 
catalyze neoplastic progression, the genomic instability 
inherent to in vitro work has slowed efforts to bring PSCs from 
the bench to the bedside. Though hESCs were first described 
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fifteen years ago, there have only been five clinical trials 
established (or planned) using these cells (see Table 1.2). 
Obviously, a greater understanding of the basic biology of 
pluripotent cells is necessary to advance their use in the 
clinic. Specifically, elucidating mechanisms of cell cycle 
control in pluripotent cells could reveal novel approaches to 
enhance the preservation of genomic integrity. 
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Chapter 2:  
Cell Cycle Control  
in  
Human Embryonic Stem Cells 
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Actively growing cells consist of four distinct phases: G1, S, 
G2, and M. Cells synthesize new DNA and separate this duplicated 
genetic information into two different cells; these phases are 
referred to as “S” and “M”, respectively. The “gap” phases, G1 
and G2, either produce the appropriate proteins for cells to 
replicate their genome (G1), or prepare the cell to divide (G2). 
These events and phases must be tightly orchestrated and 
regulated in order to ensure the appropriate growth and division 
of each cell. To this end, cells have evolved specific 
restriction points, termed “cell cycle checkpoints”, which exist 
solely to monitor progression through the cell cycle, and allow 
the cell to move to the next phase if everything has occurred 
appropriately. If an error is detected, these checkpoints 
activate and growth is arrested. 
 
While biologists have been aware of distinct phases in the life 
cycle of the cell for many years (i.e., (Boveri, 1902)), it 
wasn’t until 1970 that the molecular mechanisms of cycle control 
began to be elucidated by Leland Hartwell (Hartwell 1970). This 
work was expanded upon by Paul Nurse (see (Nurse and Thuriaux, 
1980) or (Nurse and Bissett, 1981) , for example) and Tim Hunt 
(Evans et al., 1983). Their efforts were eventually recognized 
in 2001, when all three investigators were awarded the Nobel 
Prize in Physiology or Medicine. 
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Once embryonic stem cells came into the scientific arena, 
attention was focused on their cell cycle, both out of general 
curiosity and practical purpose: if pluripotent stem cells 
commonly develop karyotypic abnormalities (despite having a 
lower mutational rate (Tichy, 2011)), perhaps their cell cycle 
checkpoints weren’t as robust as their differentiated 
counterparts. Indeed, these cells, in vivo, only exist for a few 
days – where is the evolutionary pressure for them to have 
stringent cell cycle control (for perspective, see (Damelin and 
Bestor, 2007))?  It was quickly discovered that ES cells have a 
common – though atypical – cell cycle structure. This structure 
gives us intriguing insights into the molecular mechanisms of 
genomic fidelity in pluripotent cells. 
 
This chapter will be broken down into two sections. First, the 
three major cell cycle checkpoints (G1/S, intra-S, and G2/M) 
will be discussed in the context of both differentiated and 
pluripotent cells. Second, three major proteins will be 
discussed in the context of their role in cell cycle checkpoint 
control: ataxia-telangiectasia mutated (ATM), breast cancer gene 
1 (BRCA1), and Aurora A. 
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G1 and the G1/S Checkpoint 
 
The G1 phase of the cell cycle exists to produce proteins both 
for cellular function, as well as to prepare the cell to 
duplicate its DNA in S phase. In normally functioning 
differentiated cells, prior to commitment to entering S phase, 
the Rb (retinoblastoma) protein exists in a hypo-phosphorylated 
state (van den Heuvel and Dyson, 2008). This hypo-phosphorylated 
Rb binds to the E2F-DP1 transcription factors, and this complex 
then goes on to bind to and form a large, inhibitory complex 
with HDAC (van den Heuvel and Dyson, 2008). Once the cell has 
prepared adequately to enter S, Rb becomes phosphorylated via 
the kinase action of the Cyclin D-CDK4/6 and Cyclin E-CDK2 
moieties, which breaks up the Rb-E2F-DP1-HDAC inhibitory 
complex, allowing the cells to bypass the G1/S checkpoint and 
enter S phase (Morgan, 2007). 
 
If everything doesn’t go according to plan, the cell can 
activate the G1/S checkpoint and halt growth. There are several 
events which can activate this first cellular barrier. If DNA 
damage is detected, the key phosphatase cdc25A (responsible for 
removing inhibitory phosphorylations on the Cyclin E-CDK2 
complex) becomes ubiquitinated by the SCF ubiquitin ligase 
moiety (downstream of the ATM/ATR/Chk pathway, which will be 
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discussed further), and is thusly degraded (Morgan, 2007; Skaar 
and Pagano, 2009). Without cdc25A removing inhibitory 
phosphorylations, Cyclin E-CDK2 does not become active, and the 
cell cannot enter S phase.  DNA damage also activates the p53 
pathway, arguably the most studied protein pathway in Cancer 
Biology (to be discussed later in this section). Treatment with 
TGF- β (transforming growth factor beta), a secreted protein 
which controls cellular proliferation (among other functions), 
can also activate the G1/S checkpoint through inhibition of 
cdc25A transcription via its ability to enhance p21 synthesis 
(Hanahan and Weinberg, 2000). Finally, the checkpoint can be 
activated by removal of growth factors from the media. Growth 
factor removal activates GSK-3β (Glycogen synthase kinase 3 
beta), which in turn phosphorylates Cyclin D, leading to the 
cyclin’s ubiquitination and proteasomal degradation (Diehl et 
al., 1998). Together, these events serve to ensure that the cell 
does not inappropriately enter the next phase of the cell cycle. 
 
ES cells, both mouse and human, contain several distinctions 
from their more differentiated counterparts in regards to the G1 
phase and the G1/S checkpoint. Several studies have demonstrated 
that ES cells have an abbreviated G1 phase (Becker et al., 2010; 
Filipczyk et al., 2007; Neganova et al., 2008). In mice, it was 
found that Rb is hyper- and constitutively-phosphorylated, which 
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keeps it in an inactive state (Burdon et al., 2002; Koledova et 
al., 2010). 
 
In one study of hESCs, the Cyclin D-CDK4 complex was 
consistently up-regulated, and this was a hypothesized cause for 
the observed shortened G1 phase (Becker et al., 2006). 
Conversely, a second group of investigators found that hESCs did 
not have D-type cyclins (Filipczyk et al., 2007). However, they 
did contain high levels of Cyclin E, another protein important 
for progression through G1. In opposition to these two models, 
other researchers have found that there are fluctuating levels 
of Cyclin E in hESCs, stable levels of Cyclin D, with all the 
appropriate CDKs present and active (Barta et al., 2013; 
Neganova et al., 2008). These same groups have found that CDK2, 
Cyclin A, Cyclin E, and cdc25A are all highly expressed in 
hESCs. While several labs have published contradictory results, 
these differences could be due to the fact that they all used 
different cell lines. What was universally demonstrated, 
however, was that ES cells are distinct from their somatic 
offspring. 
 
In regards to the G1/S checkpoint, it has been repeatedly 
demonstrated by independent labs and investigators that both 
human and mouse ES cells lack an active p53-p21 pathway (Bárta 
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et al., 2010; Filion et al., 2009; Momcilović et al., 2009). In 
normal cells, p53 is bound to another protein, MDM2 (mouse 
double minute 2 homolog), and kept in an inactive state (both by 
MDM2 transporting it to the cytosol and ubiquitinating it for 
proteasomal degradation (Moll and Petrenko, 2003)). In response 
to genotoxic events, p53 is activated through two major 
modifications: phosphorylation of MDM2, as well as p53 itself. 
MDM2 is phosphorylated by ATM on Ser395 and by c-Abl on Tyr394 
(Brooks and Gu, 2010). p53 is phosphorylated by ATM, ATR, Chk1, 
Chk2, and DNA-PK on Ser15 and Ser20 (Brooks and Gu, 2010). These 
phosphorylations serve to break the inhibitory MDM2-p53 
interaction, then stabilize and activate p53. Activated p53 goes 
on to enforce the G1/S checkpoint (among many other actions) by 
promoting the transcription of p21, a potent cell cycle kinase 
inhibitor. After translation, p21 binds to and inhibits the 
Cyclin-CDK2 and –CDK4 complexes, thus preventing the entrance 
into S phase (Sancar et al., 2004). 
 
The p53/MDM2/p21 story is heavily studied and documented over a 
wide range of cell types, which makes the lack of this pathway 
in hESCs so interesting. For years, the non-functional p53 
pathway meant that there was no known effective G1/S checkpoint 
in pluripotent cells. However, in 2010, Bárta and colleagues 
discovered that there was indeed a G1/S checkpoint in hESCs, and 
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that it could be activated by low-dose UV-C radiation (Bárta et 
al., 2010). This G1 checkpoint was not mediated by p53 
activation. Instead, the extremely rapid degradation of cdc25A 
seemed to be the cause (Bárta et al., 2010).  Interestingly, the 
investigators did see an increase in the levels of phospho-p53 
(and p53 levels in general), which did, in turn, cause an 
increase in the levels of p21 mRNA. However, this increase in 
p21 mRNA did not lead to an increase in the p21 protein. Upon 
further experimentation, it was discovered that pluripotent 
cells were expressing miR-302s, and these micro-RNAs were 
preventing the translation of p21 (Dolezalova et al., 2012).  In 
fact, it appears that the increased translation of p21 in 
pluripotent cells, instead of (or complementary to) enacting the 
G1/S checkpoint, causes differentiation of the cells. This was 
discovered after artificially stabilizing p53 for long periods 
with Nutlin (Maimets et al., 2008). It was also found that 
decreasing Oct4 levels (a transcription factor important for 
pluripotency) also increases p21 levels and thus, 
differentiation (Greco et al., 2007; Lee et al., 2010). 
 
Though it was thought for many years that human and mouse ES 
cells did not have a G1/S checkpoint, more recent work has cast 
doubt onto that hypothesis. However, while stem cells can 
activate a G1 checkpoint through cdc25A degradation, this arrest 
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appears “leaky”. Experiments with BrdU incorporation (and other 
assays) have found that damaged hESCs still enter S phase at an 
appreciable rate (Bárta et al., 2010; Hyka-Nouspikel et al., 
2012; Lee et al., 2010; Momcilović et al., 2009). This is 
disquieting, as most other cell types would stringently arrest 
before DNA replication to prevent the propagation of genomic 
errors. This leaky checkpoint puts pressure on the other phases 
of the cell cycle to catch what it erroneously allows to pass. 
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S Phase and the Intra-S Checkpoint 
 
If genomic lesions make it past the G1/S checkpoint, these 
insults can be replicated and turned into heritable mutations. 
Therefore, cells have evolved an intra-S phase checkpoint to 
attempt to prevent this from happening. The S phase checkpoint 
can be considered the last line of defense, as it functions to 
prevent cells from duplicating genomic errors acquired in, or 
before, S phase. Traditional activators of the intra-S 
checkpoint include replication stress, nucleotide excision 
repair, or resected breaks in DNA (Chen et al., 2012). The term 
“replication stress” usually refers to stalled replication 
forks.  Fork progress is halted when the replication complex 
encounters a genetic lesion. When the fork comes to a break, one 
DNA polymerase enzyme will arrest while the other continues on 
(Smith et al., 2010).  
 
The most heavily studied pathway controlling this checkpoint 
involves the ataxia-telangiectasia and Rad3-related (ATR) and 
Chk1 kinases. Experimental investigations have found that 
homozygous deletion of either the ATR or Chk1 genes results in 
peri-implantation embryonic lethality at embryonic day 7 (Brown 
and Baltimore, 2000; Garrett and Collins, 2011) for ATR and 
between days 3.5 - 7.5 (Takai et al., 2000) for Chk1. The only 
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known viable mutation of ATR in humans results in Seckel 
syndrome, which is characterized (as are many other disorders 
relating to DNA damage response protein mutations) by growth 
retardation and microcephaly (O’Driscoll et al., 2003).  
 
The intra-S checkpoint, as mediated by ATR, is activated when a 
stalled fork causes an excessive amount of single-strand DNA 
formation. This single-stranded DNA is immediately coated by RPA 
(replication protein A), which recruits ATR to the area via the 
ATR-interacting protein (ATRIP), a regulatory complex which 
enhances ATR binding and activity (Chen et al., 2012). ATR, once 
recruited to the lesion, becomes activated and phosphorylates 
Chk1 on Serine 317 and Serine 345. Serine 345 phosphorylation is 
essential for Chk1 activation (Takemura et al., 2006; Wilsker et 
al., 2008). Once activated, Chk1 autophosphorylates on Serine 
296, which leads to its dissociation from chromatin (Chen et 
al., 2012). Chk1 then goes on to phosphorylate and inhibit 
cdc25A (in the case of the intra-S checkpoint) or cdc25C (in the 
case of the G2/M checkpoint). 
 
As eukaryotic DNA replication occurs throughout S phase via 
multiple origins of replication distributed across the genome, 
proper regulation of S phase involves the surveillance of both 
the firing of individual origins and replication fork 
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progression after initiation. Due to the complexity of this 
process, there is considerable debate in the field over exactly 
how the intra-S checkpoint exerts its control over the cell 
cycle. For the most part, it appears to be less of an absolute 
arrest of cell activity, and more of a delay/slowing in S-phase 
progression (Ge and Blow, 2010; Ge et al., 2007; Grallert and 
Boye, 2008). Currently, it appears that the intra-S checkpoint 
represses late-origin firing (Grallert and Boye, 2008), while 
not preventing new fork initiation at sites very close to 
whatever genetic defect activated the checkpoint (Labib and De 
Piccoli, 2011). 
 
There has been very little study of the intra-S phase checkpoint 
in pluripotent cells, whether it is in mouse, human, or 
otherwise. This is surprising, given that ~60% of ES cells are 
in S phase at any given moment (Savatier et al., 2002), and, as 
previously discussed, these cells lack a strong G1/S checkpoint. 
However, one group specifically investigated the intra-S 
checkpoint of mESCs back in 2005. They discovered that treating 
cells with caffeine, a known inhibitor of both the ATM and ATR 
kinases, resulted in an S-phase delay and apoptosis (Jirmanova 
et al., 2005). Interestingly, during the course of these 
experiments, Jirmanova et al found that basal ATM and ATR kinase 
activity was relatively high. This is in direct contrast to 
38 
 
previous studies, where it was demonstrated that terminally 
differentiated cells had virtually no basal ATM/ATR activity, 
but treatment with irradiation caused rapid activation 
(Bakkenist and Kastan, 2003). To tease out which kinase was 
important for S-phase progression, Jirmanova and colleagues 
treated cells with caffeine (at a dose sufficient to inhibit 
ATR) or wortmanin, at a dose sufficient to inhibit ATM (but not 
ATR). It was found that inhibition of ATR, not ATM, was what 
caused the S-phase delay (Jirmanova et al., 2005). Seeking to 
elucidate this pathway further, they created p38α knockout 
cells. A prototypical stress-activated protein kinase, p38α is 
known to play a role in the cell cycle (for review, see (Duch et 
al., 2012)). Using these cells and caffeine, it was found that 
inhibition of ATR activates a p38α-p21 pathway which triggers 
the intra-S checkpoint. While p21 was increased, researchers 
failed to find any increase in p53 levels or activity, 
suggesting this arrest was solely due to the ATR- p38α 
interaction (Jirmanova et al., 2005). 
 
The only study done on S-phase checkpoints using human cells was 
performed with embryonal carcinoma (EC) cells. The authors 
justified their use in lieu of, and generalized their findings 
to, hESCs because “EC cells have some similarities to ES cells 
in terms of karyotypic changes, adaptation to culture, and 
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teratoma formation” (Mackenzie, 2006; Wang et al., 2009). They 
mostly compared checkpoint response in undifferentiated vs. 
retinoic acid-differentiated EC cells. Wang et al found that 
undifferentiated cells survived better and had more efficient 
DNA repair after irradiation compared to their differentiated 
counterparts (Wang et al., 2009).  Additionally, the 
undifferentiated EC cells showed an “enhanced” S-phase delay. By 
inhibiting Chk1 with the Chk1-specific inhibitor UCN-01, the S-
phase checkpoint activation was abolished (Wang et al., 2009). 
These results support Jirmanova et al’s data, indicating that, 
like their somatic counterparts, pluripotent cells rely on the 
ATR-Chk1 axis to mediate S-phase delay. 
 
While only two studies have examined the intra-S checkpoint in 
pluripotent cells, it is evident that the signaling pathway used 
is similar to differentiated cells. However, given the amount of 
time that ES cells spend in S phase, it is surprising that more 
researchers haven’t taken on projects investigating the relevant 
proteins working to ensure genomic integrity during DNA 
replication. It seems that these types of studies are 
technically demanding, thus limiting a researcher’s ability (and 
motivation) to study the intra-S checkpoint. Regardless, with a 
weak G1/S checkpoint, and an S phase checkpoint which only 
delays cycle progression (instead of outright arresting it), it 
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stands to reason that the final checkpoint before mitosis, the 
G2/M checkpoint, must be robust if a cell hopes to accurately 
pass on its genetic information. 
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G2 and the G2/M Checkpoint(s) 
 
If the G1/S or intra-S checkpoints fail to activate and prevent 
cells with genetic lesions from continuing to cycle, the G2/M 
checkpoint still stands guard against the creation of abnormal 
progeny. Similar to the G1/S checkpoint, the G2/M checkpoint 
depends on the activities of cyclins and cyclin-dependent 
kinases to function. At this point in the cell cycle, the chief 
proteins involved make up the Cyclin B/CDK1 complex. In cells 
that aren’t ready to enter mitosis, the Wee1 and Myt1 kinases 
phosphorylate CDK1 and keep it in an inactive state. Once the 
decision has been made to divide, Aurora A (along with its 
cofactor, Bora) activates and phosphorylates Plk1. Once 
activated, Plk1, in turn, phosphorylates cdc25C. Activated 
cdc25C removes the inhibitory phosphorylations from Cyclin 
B/CDK1, and promotes the progression to mitosis (for review, see 
(Morgan, 2007)). 
 
However, if the cell notices that something has gone awry in its 
normal growth pattern, it has several options available to 
arrest growth and prevent the entry into mitosis. Canonically, 
DNA damage will activate ATR and ATM, which will activate Chk1 
and Chk2 (respectively), which will, among other actions, 
phosphorylate cdc25C and target it for destruction (Ciccia and 
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Elledge, 2010; Rieder, 2011).  
 
There is a second, little-studied pathway for G2/M arrest 
involving the p38 MAP kinase. A member of the mitogen-activated 
protein kinase (MAPK) family, there are four isoforms of p38 
(alpha and beta are universally expressed, while gamma and delta 
have a tissue-specific expression pattern) (Thornton and Rincon, 
2009). Many different types of DNA/cellular damaging agents have 
been found to activate the p38 checkpoint pathway: drug 
treatment with microtubule inhibitors, topoisomerase II 
inhibitors, and histone deacetylase inhibitors; excessive 
illumination during microscopy experiments, and media changes 
(osmotic stress) (Matsusaka and Pines, 2004; Mikhailov et al., 
2004, 2005, 2007; Rieder, 2011). While it is not clear exactly 
how p38 is activated in response to DNA damage, it has been 
demonstrated that ATM activation is required for p38 activation. 
Since there are no ATM phospho-motifs on p38, it has been 
hypothesized that ATM signals through the Tao kinases, which can 
phosphorylate p38 (Thornton and Rincon, 2009). There does appear 
to be some mechanism by which p38 can be activated independently 
of ATM, but this activation has not been well characterized 
(Mikhailov et al., 2004; Reinhardt et al., 2007). Once 
activated, it is believed that p38 phosphorylates MK2, which 
then goes on to phosphorylate and inactivate cdc25B, another 
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phosphatase important for cell progression through the G2/M 
checkpoint (Lemaire et al., 2006; Manke et al., 2005). 
 
Interestingly, there is also a role for p53 in executing the 
G2/M checkpoint. Similar to its G1 activities, the ATR/ATM 
Chk1/Chk2 signaling pathway can phosphorylate and stabilize p53. 
As in G1, activated p53 promotes the transcription and 
translation of p21, which will bind to (and prevent from 
functioning) the Cyclin B/CDK1 complex (Abbas and Dutta, 2009). 
In addition to p21, p53 can also promote the function of the 14-
3-3 complex. This complex will bind to the phosphorylated 
version of the Cyclin B/CDK1 complex and export it from the 
nucleus (Abbas and Dutta, 2009). Similarly, activated p53 will 
also promote GADD45’s binding to the cyclin/CDK complex and 
direct those proteins to the cytoplasm (Thornton and Rincon, 
2009). It is important to note, however, that studies have 
demonstrated that while p53 promotes the G2/M checkpoint, it is 
not essential (see (Löbrich and Jeggo, 2007) for discussion). 
 
Classical studies demonstrated that the G2/M checkpoint was 
highly sensitive to DNA damage. Working in yeast, researchers 
found that a single double strand break (DSB) was sufficient to 
arrest cell growth (Bennett et al., 1997). This model was widely 
accepted to be the case for mammalian cells as well. However, 
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further investigation found this belief to be inaccurate. Using 
Artemis-deficient cells (which have a defect in repairing DNA 
damage, but no defect in checkpoint activation), researchers 
found a “critical threshold” of DSBs which cells would have to 
endure before checkpoint activation (Deckbar et al., 2007). This 
threshold was approximately 20 DSBs. Deckbar et al found that if 
DNA damaging agents caused fewer than 20 DSBs, the G2/M 
checkpoint would not activate. If these damaging agents caused 
more than 20 breaks, cycling would pause until the cells had 
repaired enough damage to get below the critical threshold 
(Deckbar et al., 2007). Therefore, there appeared to be a dose-
dependent length of arrest – the higher the levels of damage, 
the longer the cells would remain arrested. 
 
This dose-dependent length of arrest is important, because tumor 
cells show a sort of “adaptation” to cell cycle arrest. Was this 
threshold model accurate, or were cells, instead of repairing 
enough damage to get under the critical 20 DSB threshold, just 
adapting to the DNA damage and continue to grow? After all, 
under continuous exposure to 6 Gy of IR, tumor cells eventually 
break free of arrest and enter mitosis with multiple, unrepaired 
breaks (Bartek and Lukas, 2007; Syljuåsen et al., 2006). This 
adaptation appears to be mediated by the resumption of Plk1 
activity and the inhibition of Chk1 (Bartek and Lukas, 2007; 
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Syljuåsen et al., 2006). However, what was observed in these 
tumor lines does not appear to be the case for somatic (non-
neoplastic) cells. In the Artemis-deficient cells, which could 
not repair the DSBs (but were otherwise normal), cell cycle 
arrest continued for many days (Deckbar et al., 2007).  
 
Unfortunately, there have been few studies conducted which 
directly investigate G2/M checkpoint activation in embryonic 
stem cells (though several groups have investigated cancer stem 
cell checkpoint function – this will not be discussed). One of 
the earliest reports looked at the Akt/Protein kinase B (PKB) 
pathway in mESCs. Akt is a critical protein mutated in many 
human cancers. It is involved in the regulation of many cellular 
functions including metabolism, cell growth, apoptosis and 
survival (for review, see (Song et al., 2005)). Using PTEN 
knockout mESCs, Kandel and colleagues found that they could 
override the G2/M checkpoint after irradiation (PTEN is a 
phosphatase responsible for removing activating phosphorylations 
from the Akt molecule) (Kandel et al., 2002). They assert that 
normal Akt signaling is needed for mESCs to properly transverse 
the G2/M checkpoint, however, they offer no pathway/mechanism 
for this opinion (Kandel et al., 2002).  
 
Another set of investigators examined the effect of Rad9 
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knockout on mESCs. Rad9, together with Rad1 and Hus1, form the 
“9-1-1” complex, which functions in DNA repair and activation of 
cell cycle checkpoints (Doré et al., 2009; Sohn and Cho, 2009; 
Xu et al., 2009; Zhang et al., 2011). The 9-1-1 complex executes 
these actions by first being loaded onto damaged chromatin. 
After loading, the 9-1-1 complex binds TopBP1, which stimulates 
ATR-mediated Chk1 phosphorylation and downstream events (such as 
cell cycle arrest) (Delacroix et al., 2007). Zhang et al showed 
that Rad1 knockout mESCs were defective in G2/M arrest after 
both UV- and gamma-irradiation (Zhang et al., 2011). 
 
Recently, the canonical DNA damage signaling pathway involving 
ATM/Chk2/p53 was investigated in hESCs. Using gamma radiation, 
Momcilovic et al demonstrated that ATM was phosphorylated and 
localized to sites of DSBs within 15 minutes, and that cells 
arrested in G2, not G1 (Momcilović et al., 2009). The peak level 
of ATM, Chk2, and p53 phosphorylation was seen within 1 hour of 
IR. Interestingly, it was observed that the cell cycle arrest 
was temporary – after 16 hours, the irradiated cells resumed 
proliferation (Momcilović et al., 2009). It was unclear whether 
this release was due to the hESCs repairing the damage to get 
below the critical threshold of DSBs, or, like tumor cells, they 
can eventually overcome the block even in the presence of 
significant damage. To confirm that ATM was responsible for 
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mediating arrest, Momcilovic et al used the ATM-specific kinase 
inhibitor, KU-55933, to pharmacologically inhibit ATM. Treating 
with KU-55933, it was observed that the G2 arrest could be 
abolished 2 hours after irradiation. Notably, it was observed 
that ATM could only be inhibited by using 10x the normal dose 
(10 μM is sufficient to inhibit ATM in other cell types, here, 
100 μM was used) (Momcilović et al., 2009). This is curious, as 
other labs have used KU-55933 to inhibit ATM in hESCs at 
standard dosages (Adams et al., 2010a, 2010b). While the authors 
claim that KU-55933 at 100 μM should still, theoretically, only 
inhibit ATM, it is possible that such a high concentration could 
inhibit other kinases involved in the DNA damage response/growth 
and proliferation, such as DNA-PK or mTOR (per the IC50 values 
provided on www.tocris.com). Further study is warranted in this 
area. 
 
While there is a paucity of reports investigating the G2/M 
checkpoint in ES cells, it does appear that their mechanisms for 
arrest are similar to differentiated cells, at least insofar as 
arrest caused by DNA damaging agents. However, DNA damage is not 
the only way to cause a G2/M arrest. There is another, distinct 
checkpoint which takes place at the border of mitosis – the 
decatenation checkpoint.   
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The decatenation checkpoint 
 
After replication, daughter chromatids contain areas of 
entanglement, or catenations. These catenanes form when two 
replication forks meet, and the parental and daughter strands 
cannot separate (Downes et al., 1994). The cell must relieve 
these catenations for normal replication to complete. If 
catenations are not resolved, a distinct G2/M cell cycle 
checkpoint activates – the decatenation checkpoint. If the 
checkpoint does not activate, nondisjunction and chromosome 
breakage can occur, causing genomic aberrations in daughter 
cells. Topoisomerase II-α is the enzyme responsible for 
decatenation and decatenation checkpoint signaling (Bower et 
al., 2010a). Topoisomerase II untangles chromosomes via the same 
mechanism by which it relieves helical stress after replication: 
by binding to DNA, cutting both stands, passing a second DNA 
duplex through the cut, and re-ligating the cut strands (for 
review, see (Wang, 2002)).  
 
Failure to adequately decatenate chromosomes activates the 
decatenation checkpoint. Currently, the checkpoint signaling 
cascade is not well characterized. A hypothesis of the pathway 
is given in Figure 2.1. Initial studies of the checkpoint 
examined the proteins involved in the DNA damage response  
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pathway, ATM and ATR. It was found that ATR, not ATM, mediated 
the checkpoint, and that BRCA1 was also involved (Deming et al., 
2002). Interestingly, experimental data indicated that while ATR 
was essential for checkpoint activation, it wasn’t acting 
through the traditional Chk1 pathway. Instead, it suggested that 
ATR mediated the decatenation checkpoint by excluding Cyclin 
B/CDK1 complexes from the nucleus through an unknown mechanism 
(Deming et al., 2002). A later study using lung cancer cell 
lines found that inhibiting decatenation caused 
autophosphorylation of ATM, but this finding was not followed up 
on (Nakagawa et al., 2004). Recently, studies have surfaced 
stating that ATM, not ATR, mediates the checkpoint (Bower et 
al., 2010b) (the same group that published the initial, 
conflicting paper on ATM/ATR and decatenation checkpoint 
signaling), or that ATM and ATR have complementary roles in the 
checkpoint (Greer Card et al., 2010). 
 
Murine embryonic stem cells and CD34+ human hematopoietic 
progenitor cells were found to have a defective decatenation 
checkpoint (Damelin et al., 2005). This defect is hypothesized 
to be a cause of the chromosomal aberrations witnessed in 
culture (i.e., catenations are not resolved, nondisjunction 
occurs during mitosis, and a gain of chromosome 12 or 17 is 
acquired, conferring some sort of growth advantage). It is 
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theorized that the stem cells harvested from blastocysts and 
expanded in vitro have had little selection pressure for 
stringent cell cycle regulation, as their in vivo environment 
requires few divisions (Damelin and Bestor, 2007). 
 
Unlike the G2/M DNA damage checkpoint, there have been 
relatively few papers published on the molecular underpinnings 
of the decatenation checkpoint in the nearly 20 years since it 
was first described, and the few papers that have been published 
present contradictory results. Additionally, the only paper 
which examined the decatenation checkpoint in ES cells proposes 
a tantalizing mechanism by which aneuploidy could develop in 
pluripotent cells. Clearly, more work needs to be done in this 
area to enhance our understanding of the decatenation checkpoint 
and how manipulation of this pathway can be used to enhance stem 
cell genomic integrity. 
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Proteins involved in checkpoint signaling 
 
The field of study regarding our molecular understanding of cell 
cycle control has exploded since the groundbreaking work done in 
the 1970’s. Thousands of manuscripts, books, and doctoral 
dissertations have been authored on the intricate protein 
signaling networks that govern the growth and genomic integrity 
of individual cells. The present work will focus on three 
proteins which are known to play key roles in checkpoint 
regulation: ATM, BRCA1, and Aurora A. As it is not feasible to 
accurately convey the current state of knowledge on each of 
these proteins, several references to seminal books and review 
papers are given in the following sections.   
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Ataxia Telangiectasia Mutated  
 
Ataxia telangiectasia (Online Mendelian Inheritance in Man 
(OMIM) database ID: 208900) is a rare disease inherited in an 
autosomal recessive manner (Lavin, 2008; Perlman et al., 2012). 
Its pathology is characterized by progressive neurodegeneration 
(primarily in the cerebellum), telangiectasia (dilation of blood 
vessels, mainly around the mouth and eyes), immune deficiency, 
thymic and gonadal atrophy, a predisposition to cancer, acute 
sensitivity to radiation, growth retardation, premature aging, 
and insulin resistance (Shiloh and Ziv, 2013). Typically, 
affected patients express a truncated form of ATM or one plagued 
by missense mutations. Many of the major symptoms of ataxia 
telangiectasia can be attributed to a defective cellular 
response to endogenous, physiological DSBs or by exogenous DNA 
damaging agents. 
 
The protein responsible for the disease, ATM, is a 350 kDa 
protein containing 3,056 amino acid residues. A serine/threonine 
kinase, ATM targets and phosphorylates serine-glutamine (SQ) 
and/or threonine-glutamine (TQ) motifs on substrate proteins. 
Currently, there is a distinct lack of structural information on 
ATM, as it has yet to be crystallized (due to the technical 
challenge of crystallizing this particular molecule) (see Figure 
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2.2 for a schematic of the ATM protein). ATM acts as a 
“transducer” of DNA damage, signaling other proteins when damage 
is detected. Other protein complexes bind to the lesions first 
(the “sensors” of DNA damage) and bring ATM in to activate a 
global cellular response to DNA damage (for review, see (Shiloh 
and Ziv, 2013)). As discussed in the previous sections, this 
signal transduction is crucial to G1/S and G2/M checkpoint 
activation. 
 
ATM is a member of the PI3K-like protein kinase family (PIKK). 
Two other members of the PIKK family play key roles in the DNA 
damage response (DDR) and cell cycle checkpoint signaling: ATR 
and DNA-PK (DNA-dependent protein kinase catalytic subunit). ATR 
(as discussed earlier) also acts as a signal transducer, often 
performing overlapping functions with ATM. DNA-PK is best known 
for its role in non-homologous end joining (NHEJ), where it 
forms a holoenzyme with the KU-70/KU-80 heterodimer (Hill and 
Lee, 2010; Neal and Meek, 2011; Shiloh and Ziv, 2013). 
Interestingly, cells from ataxia telangiectasia patients are 
able to perform some of functions of the DDR which are known to 
be ATM dependent (although in a somewhat diminished capacity) 
(Tomimatsu et al., 2009). It is possible that some other 
proteins in the PIKK family (like ATR and DNA-PK) can “fill in” 
for ATM and take on some of the workload in its absence. 
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While there are conflicting reports over exactly how (and what) 
activates ATM in response to DNA damage (or other agents - to be 
discussed), the most accepted model begins with the 
Mre11/Rad50/Nbs1 complex, commonly known as the MRN complex. The 
MRN complex is a highly conserved group of proteins shown to 
rapidly localize to sites of DNA damage and play an important 
role in homologous recombination repair (HRR), NHEJ, and cell 
cycle checkpoint signaling (see (Lavin, 2008), for review). 
Mre11/Rad50/Nbs1 binds to sites of DSBs and tethers the two 
broken ends together. This binding is crucial for the 
recruitment and activation of ATM. Under normal conditions, ATM 
exists in the cell as an inactive dimer, and, upon recruitment 
to sites of DSBs by the MRN complex, activates and dissociates 
into two monomers (Bakkenist and Kastan, 2003). During the 
activation sequence, ATM is autophosphorylated on Serine 367, 
Serine 1893, and Serine 1981 (Czornak et al., 2008) (see Figure 
2.2 for a summary of the key activating post-translational 
modifications of ATM). While there is conflicting information on 
the subject, it is currently hypothesized that ATM’s 
autophosphorylation (specifically on Serine 1981) is not 
required for its monomerization or recruitment to sites of DSBs, 
rather, the autophosphorylation is essential for retention at 
sites of genetic lesions (Bensimon et al., 2010; Lee and Paull, 
2005; So et al., 2009). However, a group of investigators did 
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find evidence supporting the notion that autophosphorylation is 
the cause of monomer formation (Bakkenist and Kastan, 2003). 
 
Other evidence-based models have been brought forward suggesting 
that the DSB-MRN complex pathway may not tell the entirety of 
the story. Michael Kastan’s lab published a report demonstrating 
that the conformational change in chromatin, which follows DSB 
formation, rather than the DSB itself, is what causes ATM 
activation (Bakkenist and Kastan, 2003). A later paper supported 
this model by showing that artificial “tethering” of ATM to 
chromatin could activate the ATM-dependent DDR (Soutoglou and 
Misteli, 2008). In contrast, other work has suggested that ATM 
needs to interact with broken DNA to become activated (You et 
al., 2007), and that oligonucleotides from resected DSBs have 
the ability to activate ATM (Jazayeri et al., 2008). It is 
likely, given ATM’s widespread responsibilities in genomic 
surveillance, that most, if not all of these models contain some 
sort of truth. Further work is needed in this area to clarify 
the conditions under which ATM is activated. 
 
Over the past several years, many novel pathways involving ATM 
have been described. Investigators have shown that ATM can 
activate NF- κB, which promotes the transcription of anti-
apoptotic genes (Hadian and Krappmann, 2011; Rashi-Elkeles et 
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al., 2006). It does this by phosphorylating IKKγ, a subunit of 
the IκB kinase (IKK) family (McCool and Miyamoto, 2012). In 
unstimulated cells, the IκB proteins inhibit NF- κB by keeping 
it sequestered in the cytoplasm. Once IKKγ is phosphorylated and 
activated by ATM, it, in turn, phosphorylates IκBα, which leads 
to IκB ubiquitination and eventual degradation (Shiloh and Ziv, 
2013). Once these inhibitory proteins are degraded, NF-κB is 
free to enter the nucleus and begin transcription. 
 
ATM is also involved in the oxidative stress response. Reactive 
oxygen species exert their damage by direct oxidation of 
cysteine residues, disrupting the structure and function of 
important intracellular proteins. However, the oxidation of 
certain cysteine residues in ATM catalyzes the formation of 
active, disulphide-crosslinked ATM dimers which are then able to 
enact a global cellular response to oxidative stress (Guo et 
al., 2010). Along these same lines, it has been discovered that 
ATM is important in the generation of the anti-oxidant cofactor, 
NADPH. NADPH is produced by the pentose phosphate cycle and 
promotes the regeneration of GSH (reduced glutathione)(Rush et 
al., 1985). ATM comes into play by phosphorylating heat shock 
protein 27 (HSP27), which binds to and stimulates the activity 
of glucose-6-phosphate dehydrogenase (G6PD), a key enzyme in the 
pentose phosphate cycle (Cosentino et al., 2011). These 
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oxidative stress functions of ATM are hypothesized to be one of 
the causes of the neuronal degeneration witnessed in ataxia 
telangiectasia patients. Neurons, one of the most active cell 
types in the body, generate a large amount of oxidative, 
metabolic byproducts. A lack of functional ATM means these 
harmful byproducts are free to cause significant damage to the 
cell, leading to apoptosis or necrosis. 
 
Since the ATM gene was first identified in 1995, it has been the 
subject of numerous studies approaching the molecule from 
various angles. Currently, a PubMed search for “atm kinase” 
returns almost 4,000 results. These reports all provide evidence 
for ATM’s significant role in protecting the integrity of the 
genome. However, recent studies have made clear that ATM’s role 
in genetic protection does not begin and end with the DNA damage 
response. As more work is done with this kinase, we will begin 
to elucidate answers to questions we didn’t even know to ask. 
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BRCA1 
 
In 1994, researchers made a major breakthrough in uncovering the 
cause of hereditary breast cancer by discovering the “breast and 
ovarian cancer susceptibility gene 1”, now colloquially referred 
to as BRCA1 (Miki et al., 1994). BRCA1 is a relatively large 
protein, weighing approximately 220 kDa and spanning 1863 amino 
acids. The N-terminus contains a RING finger domain, while the 
C-terminus contains two BRCT domains. The intervening sequence 
contains a nuclear export signal, two nuclear localization 
signals (Chen et al., 1996), a DNA binding domain, as well as a 
serine-glutamine (SQ) cluster domain (refer to Figure 2.3 for a 
schematic of the BRCA1 protein, as well as important binding 
partners). 
 
BRCA1’s N-terminal RING domain is an E3 ubiquitin ligase and 
forms a complex with another RING domain-containing protein, 
BARD1 (Wu et al., 1996). This heterodimer has been shown to 
autoubiquitinate BRCA1, which, in turn, increases BRCA1’s 
ubiquitin ligase activity (Mallery et al., 2002; Nishikawa et 
al., 2004; Wu-Baer et al., 2003). The BRCA1-BARD1 interaction 
promotes nuclear localization by masking the BRCA1 nuclear 
export signals, leaving the dual nuclear localization signals 
uncovered (Fabbro et al., 2002; Rodriguez et al., 2004). BRCA1’s  
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ubiquitin ligase activity is important for normal cellular 
function, including the G2/M checkpoint and mitosis. 
 
The SQ cluster domain is a region of serine and threonine 
residues ranging from amino acids 1241-1530. These residues are 
phosphorylated by ATM and ATR in response to DNA damage (among 
other stimuli). ATM is the main kinase that phosphorylates BRCA1 
in response to ionizing radiation (Cortez et al., 1999; Gatei et 
al., 2000). ATR has redundant/backup phosphorylation duties 
to/for ATM, and, as previously mentioned, is activated by 
stimuli such as ultraviolet radiation and stalled replication 
forks (Tibbetts et al., 2000). The redundant serine residues 
that are phosphorylated by ATM and/or ATR are S1387, S1423, 
S1457, and S1524. Serine 1387 is phosphorylated only by ATM (in 
response to irradiation), while serine 1457 is uniquely 
phosphorylated by ATR in response to ultraviolet radiation 
(Gatei et al., 2001). 
 
Many of these phosphorylations seem to have direct consequences 
for cell cycle control. Serine 1387 phosphorylation is involved 
in the intra-S checkpoint, whereas the phosphorylation of 
serines 1423 and 1524 is important for G2/M checkpoint 
activation (Xu et al., 2001, 2002). Additional phosphorylations 
outside of the serine cluster domain are also important for 
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checkpoint control. For example, Chk2 phosphorylates BRCA1 on 
serine 988 in response to microtubule damage, inhibiting the 
microtubule nucleation activity of BRCA1 and preventing the 
proper transition to, and through, mitosis (Chabalier-Taste et 
al., 2008). Additionally, Ouchi et al found that phosphorylation 
of serine 308 by the Aurora-A kinase is necessary to 
successfully traverse the G2/M checkpoint (Ouchi et al., 
2004)(discussed further in this chapter, as well as Chapter 5). 
 
The BRCA1 BRCT domains bind phospho-proteins containing the 
phospho-serine-X-X-phenylalanine (pSer-X-X-Phe) motif, where “X” 
represents any amino acid (Manke et al., 2003; Yu et al., 2003). 
The four most heavily studied BRCT binding partners of BRCA1 are 
Abraxas, BACH1, CtIP, and PALB2 (Caestecker and Van de Walle, 
2013; Wang et al., 2007; Yu and Chen, 2004). Abraxas bridges 
another protein, RAP80, to BRCA1. This complex, along with the 
BRCA1-BACH1 and BRCA1-CtIP complexes, have all been shown to be 
involved in the homologous repair of DSBs (Litman et al., 2005; 
Sartori et al., 2007; Yan et al., 2007). The BRCA1-Abraxas-RAP80 
complex is important because RAP80 localizes BRCA1 to sites of 
DSBs through its dual ubiquitin-interacting motifs, which are 
attracted to polyubiquitinated H2AX (a post-translation 
modification of H2AX mediated by MDC1 which occurs at sites of 
DSBs) (Caestecker and Van de Walle, 2013; Sobhian et al., 2007). 
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Additional work has demonstrated that BACH1, a helicase, is 
involved in S-phase progression, and it has been shown that 
mutations in BACH1 interferes with normal DSB repair, suggesting 
that the BRCA1-BACH1 interaction is essential to BRCA1’s DNA 
repair function (Cantor et al., 2001; Kumaraswamy and 
Shiekhattar, 2007). 
 
The final major BRCA1-BRCT interacting protein, CtIP, has been 
shown to be important for BRCA1’s function in the G2/M 
checkpoint. In 2004, it was found that the BRCA1-CtIP complex 
only existed in the G2 phase of the cell cycle, and that this 
interaction is necessary for the DNA damage-induced 
phosphorylation of Chk1 and activation of the G2/M checkpoint 
(Yu and Chen, 2004). Later, the same group demonstrated that 
CtIP was ubiquitinated by BRCA1. This ubiquitination does not 
signal CtIP for destruction, rather, it promotes CtIP’s 
association with chromatin following DNA damage, and was also 
found to be necessary for G2/M checkpoint activation (Yu et al., 
2006).  
 
BRCA1’s role in cell cycle control goes far beyond its 
interaction with CtIP. The BRCT domain has also been found to 
function in transcription of the p21 promoter through its 
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association with p53 (Chai et al., 1999; Li et al., 1999; Ouchi 
et al., 1998; Zhang et al., 1998). After DNA damage, CtIP can 
dissociate from BRCA1, allowing p53 to bind which leads to the 
transcriptionally-mediated aspect of cell cycle control (as well 
as DNA repair). Along these same lines, BRCA1 can also associate 
with the acetyltransferase complex CBP/p300, which further 
increases the BRCA1-p53 dependent transcriptional activity (Pao 
et al., 2000). As p53 has been shown to be active in both the 
G1/S and G2/M checkpoints (Agarwal et al., 1995), it is probable 
that BRCA1 is also involved in both of these major checkpoints. 
 
Another experimentally validated model for BRCA1’s function in 
the cell cycle revolves around its regulation of centrosomes. 
Centrosomes are cellular organelles that nucleate microtubules 
throughout interphase and mitosis (Moritz et al., 1995). 
Centrosomes duplicate once per cell cycle and, during mitosis, 
move to opposite ends of the cell forming the bipolar mitotic 
spindle (see (Morgan, 2007) for review). BRCA1, along with 
BARD1, have been found to localize to the centrosome and ensure 
that centrosomal duplication occurs only once per cell cycle, a 
process which is important in preventing the formation of 
multipolar mitotic spindles, unequal chromosome segregation, and 
aneuploidy (Sankaran et al., 2005, 2006; Starita et al., 2004). 
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In cells containing BRCA1 mutations, centrosomal amplification 
and aneuploidy are commonly recorded events, leading to and 
enhancing the neoplastic transformation of these cells (Deng, 
2001; Schlegel et al., 2003; Starita et al., 2004; Xu et al., 
1999). The BRCA1-BARD1 complex ubiquitinates γ-tubulin, a 
modification that regulates the initial nucleation of 
microtubules at centrosomes (Sankaran et al., 2005). Microtubule 
nucleation involves taking free tubulin dimers and assembling 
them into a stable aggregate known as “nucleation centers”. The 
most important nucleation center is known as the γ-tubulin ring 
complex, or γ-TuRC. It is here where the BRCA1-BARD1 heterodimer 
exerts its regulation, by ubiquitinating and prevening excessive 
nucleation and spindle formation (Sankaran et al., 2007; Starita 
et al., 2004).  Recent work has demonstrated that the protein 
CRM1 (chromosome region maintenance 1) mediates the nuclear 
export of BRCA1, as well as its localization to centrosomes 
(Brodie and Henderson, 2012). This same report showed that 
Aurora A’s binding and phosphorylation of BRCA1 was important 
for its centrosomal retention (discussed further in Chapter 4). 
 
BRCA1’s ubiquitin-mediated cell cycle control is not limited to 
centrosomes. It was previously shown that in response to DNA 
damage, BRCA1 was crucial to G2/M arrest by its downregulation 
of Cyclin B/CDK1 and Cdc25C (Yarden et al., 2002, 2012). 
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However, the mechanism by which this occured was unknown. In 
late 2012, the Yarden lab demonstrated that this downregulation 
was due to BRCA1’s E3 ubiquitin ligase activity. After DNA 
damage (induced by either γ-irradiation or Neocarzinostatin), 
the BRCA1-BARD1 complex polyubiquitinates both Cyclin B and 
Cdc25C, which leads to their proteasomal degradation (Shabbeer 
et al., 2012). Without these crucial proteins, the transition to 
mitosis cannot occur. 
 
BRCA1, much like ATM, clearly plays diverse and important roles 
in the protection of cellular structure and function. While a 
number of stimuli have been shown to cause distinct post-
translation modifications of BRCA1 (leading to downstream 
effects), much investigation remains to be done to fully 
elucidate all the mechanisms by which BRCA1 exerts its caretaker 
functions. As it stands, BRCA1 appears to have widespread 
influence over the life cycle of the cell.  
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Aurora A kinase 
 
Aurora A is a 48 kDa protein comprised of 403 amino acids, with 
its important kinase domain spanning from amino acids 133-383. 
It was first crystallized in 2002, and there are now at least 57 
crystal structures of Aurora A in complexes with other proteins 
or pharmacologic inhibitors (Nikonova et al., 2013). 
 
In regards to the cellular life cycle, it has been well 
documented that Aurora A functions in both centrosomal 
regulation and the progression through mitosis. In S phase 
(after centrosomal replication), Aurora A begins to accumulate 
at the centrosomes, where it is responsible for recruiting a 
number of proteins to the pericentrosomal material, such as γ-
tubulin, centrosomin, LATS2, TACC, and NDEL1 (Abe et al., 2006; 
Conte et al., 2003; Hannak et al., 2001; Mori et al., 2007; Toji 
et al., 2004). These proteins, along with Aurora A, increase the 
microtubule nucleation activity of the centrosomes. 
 
The events responsible for Aurora A activation are not clear-
cut. Indeed, there are a multitude of different interactions and 
phosphorylations which can influence Aurora A’s activity. The 
earliest described (and most thoroughly studied) cofactor of 
Aurora A activation is TPX2. TPX2 binds to Aurora A and helps 
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target it to the mitotic spindles (Kufer et al., 2002). Once 
TPX2 binds, the activation segment of Aurora A moves inside the 
kinase’s catalytic pocket, inducing the autophosphorylation of 
threonine 288 (Bayliss et al., 2003; Eyers et al., 2003). The 
binding of TPX2 also protects Aurora A from the deactivating 
functions of protein phosphatase 1 (PP1) by “hiding” the 
threonine 288 residue from the enzymatic activity of PP1 
(Bayliss et al., 2003; Eyers et al., 2003). 
 
Two other important cofactors are Ajuba and Bora, to which 
Aurora A binds and phosphorylates. Circuitously, Ajuba binding 
is necessary for Aurora A autophosphorylation (which, in turn, 
phosphorylates Ajuba) (Hirota et al., 2003). This activation 
takes place at the centrosomes, and is crucial for the 
activation of the Cyclin B/CDK1 complex. Similarly to Ajuba, 
Bora binding and phosphorylation enhances Aurora A’s kinase 
activity (Hutterer et al., 2006), though the exact function of 
this interaction remains unclear. Studies in Drosophila 
identified Bora as important for asymmetric cell division, which 
would play into Aurora A’s role in regulating mitosis (Berdnik 
and Knoblich, 2002).  
 
There are several additional proteins which experimental data 
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has demonstrated to be involved in Aurora A’s activation (see 
(Nikonova et al., 2013) for a helpful summary). At present, 
however, the literature is murky in regards to what exactly 
these proteins are doing, and why. This likely stems from the 
fact that several different model systems have been used to 
study Aurora A (Xenopus, Drosophila, etc.) and not all 
functions/interactions are conserved across species. The big 
picture question involves solving how all these cofactors work 
together to regulate Aurora A’s function. 
 
Once activated, Aurora A is involved in several downstream 
pathways (see Figure 2.4 for an overview of key Aurora A 
functions). As previously stated, Aurora A (coupled with Bora) 
is key in activating the Cyclin B/CDK1 complex. This complex is 
initially gathered and activated at centrosomes, and Aurora A 
positively reinforces this activation (Jackman et al., 2003; De 
Souza et al., 2000). The hypothesized signaling pathway has an 
activated Aurora A/Bora complex phosphorylating and activating 
Plk1. Plk1, once activated, feeds into the loop of recruiting 
more Aurora A to the centrosomes, where Aurora A can then 
phosphorylate Cdc25B (Dutertre et al., 2004). Cdc25B is required 
for the initial centrosomal activation of the Cyclin B/CDK1 
complex (Lindqvist et al., 2005), providing a mechanism by which 
Aurora A can directly push cells through the G2/M transition. 
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Several studies have investigated the consequences of Aurora A 
mutation/inhibition on centrosomal maturation and bipolar 
spindle formation. Often, depletion of Aurora A leads to 
monopolar spindle formation, preventing the accurate progression 
through mitosis (Glover et al., 1995; Hannak et al., 2001; Liu 
and Ruderman, 2006; Roghi et al., 1998). There are several 
possible mechanisms by which this takes place. Aurora A has been 
shown to phosphorylate Eg5, a kinesin which is involved in 
centrosome separation (Giet et al., 1999). However, it is not 
known if this phosphorylation is essential for Eg5’s activity. 
 
Aurora A also targets and phosphorylates a protein called LIMK1. 
As is the case with Eg5, LIMK1 is a proposed regulator of 
bipolar spindle formation, but it is not known if Aurora A’s 
phosphorylation is important for this function (Chakrabarti et 
al., 2007; Ritchey et al., 2012). This phosphorylation is 
important, however, for the mitotic co-localization of Aurora A 
and LIMK1. Additionally, Aurora A is known to affect astral 
microtubules, which connect centrosomes to the cell cortex and 
can influence bipolar mitotic spindle formation (Giet et al., 
1999). Further work needs to be done in this area in order to 
fully elucidate how Aurora A contributes to spindle formation, 
and, in return, function (see (Nikonova et al., 2013) for 
discussion). 
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Finally, once Aurora A has completed its duties in shepherding 
cells through mitosis, it needs to be degraded (unlike ATM and 
BRCA1, which function throughout the cell cycle). This is done 
though an E3 ubiquitin ligase named the Anaphase Promoting 
Complex/Cyclosome (APC/C) (Vader and Lens, 2008). At the end of 
mitosis, Aurora A is targeted for destruction, a mechanism by 
which it is ensured that low levels of mitosis-promoting 
proteins exist in G1. However, mutations in Aurora A (or other 
proteins) can arise which prevent its destruction, enhance its 
function, or alter key activities. When this occurs, malignancy 
can result. 
 
Aurora A has been shown to be mutated in a number of cancers 
(see (Katayama et al., 2003), for example). However, isolated 
mutations in Aurora A are not enough to induce malignancy (Zhou 
et al., 1998), indicating that other oncogenic events must take 
place before a cancerous Aurora A phenotype can arise (Tatsuka 
et al., 2005). Aurora A is located on chromosome 20q13.2, a 
region which is frequently amplified in solid tumors (Nikonova 
et al., 2013). Typical features of pathologic Aurora A function 
include amplified centrosomes, multipolar spindles, aneuploidy, 
and deficient cell cycle checkpoints (Meraldi et al., 2002; 
Nikonova et al., 2013).     
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Aurora A’s neoplastic potential has been shown to depend on p53 
status. Aurora A directly phosphorylates p53, and, like ATM and 
BRCA1, stabilizes it, leading to downstream transcriptional 
events (Katayama et al., 2004; Liu et al., 2004). In mouse 
models, Aurora A was unable to produce tumors except in a p53-
knockout background (Fukasawa et al., 1996). This is presumed to 
be caused by the aneuploid cells coming up against the p53-
mediated G1/S checkpoint which, when intact, activates and sends 
cells into senescence/death (Fukasawa et al., 1996). While 
Aurora A can activate p53 through phosphorylation, it can also 
inhibit it. By phosphorylating Serine 315 of p53, Aurora A 
increases the MDM2-dependent degradation of the protein 
(Katayama et al., 2004). Conversely, p53 can bind to the 
catalytic domain of Aurora A, inhibiting it (Chen et al., 2002; 
Eyers et al., 2003). 
 
Recently, this relationship was highlighted as a key factor in 
maintaining stem cell pluripotency. Using a short hairpin (sh) 
RNA screen, Lee et al found that depleting Aurora A resulted in 
compromised self-renewal, leading to differentiation. They 
discovered that loss of Aurora A leads to upregulated p53, a 
finding which supports previous studies (i.e. (Katayama et al., 
2004). Phosphorylation of p53 by Aurora A also downregulated the 
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p53-mediated suppression of iPS cell reprogramming (Lee et al., 
2012). Few other studies have been conducted on Aurora A and ES 
cells. In conditional knockout mice, it was shown that 
differential Aurora A expression can influence early mouse 
embryo patterning (while complete knockout was found to be 
embryonically lethal) (Yoon et al., 2012). Additionally, it was 
also shown (again in mice) that Aurora A is crucial for 
epidermal differentiation and development. Epidermal deficiency 
of Aurora A was shown to promote aberrant mitosis, mitotic 
slippage, and cell death (Torchia et al., 2013). Clearly, more 
research is needed in this area to clarify what role Aurora A 
plays in both pluripotent and somatic cells. 
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Chapter 3:  
Modulation of ATM function:  
effects on the cell cycle 
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Over the past fifteen years, the successful culture and 
propagation of human embryonic stem cells has generated new hope 
for the development of novel therapies based in regenerative 
medicine. Unlike somatic cells, hESCs can be cultured in an 
undifferentiated state for long periods, while retaining the 
ability to form cells of all three embryonic germ layers 
(Thomson et al., 1998). Unfortunately, therapies have been slow 
to develop, as obstacles to expanding these cells ex vivo have 
arisen.  
 
One such obstacle is aneuploidy. Mouse, human, and induced 
pluripotent stem cells fail to remain euploid after prolonged 
culturing (Draper et al., 2004; Longo et al., 1997; Mayshar et 
al., 2010). If aneuploid/genetically unstable hESCs are 
transplanted, cancer can result (Amariglio et al., 2009). 
Malignant transformation arises from cells acquiring errors in 
their genome, resulting in a gain of function or loss of 
regulation. To prevent these genomic flaws from inciting 
unwarranted growth, cells have evolved methods to arrest the 
cell cycle and repair the detected mistakes. If the DNA cannot 
be repaired, cells undergo apoptosis, a small sacrifice to 
preserve the larger organism. If cells fail to arrest and 
apoptosis does not occur, cancer can develop, leading to loss of 
function and, if left untreated, death.   
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As hESCs display a shortened G1 phase (2.5 – 3 hours) and a 
“leaky” G1/S checkpoint (Boheler, 2009; Nouspikel, 2013), there 
is increased pressure on the G2/M checkpoint to detect any 
genetic abnormalities and arrest the cell appropriately. Two 
significant events will trigger a checkpoint at the mitotic 
boundary: DNA damage and/or catenated chromatin (Downes et al., 
1994). The fact that DNA damage can produce genomic instability 
is a well-known and well-studied process (see (Abbas et al., 
2013), for example. However, what role decatenation and the 
decatenation checkpoint plays in retaining genetic fidelity is 
much more poorly understood. If a cell fails to properly 
decatenate its chromosomes, a cell cycle checkpoint (distinct 
from the DNA damage checkpoint) activates, arresting cells at 
the G2/M phase (Downes et al., 1994). If the checkpoint does not 
activate, and cells complete division with catenated 
chromosomes, nondisjunction and breakage can occur. This can 
lead to translocations and other abnormalities in daughter 
cells. 
 
Previous work has described a deficient decatenation checkpoint 
in mouse embryonic stem cells (Damelin et al., 2005), and 
progress has been made towards characterizing the checkpoint’s 
pathway. Recently, it has been posited that the DNA damage 
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signaling protein ATM mediates the decatenation checkpoint 
(Bower et al., 2010b), though the exact cascade remains unknown. 
ATM’s potential involvement is significant because previous work 
from our lab has demonstrated that ATM, while present in hESCs, 
does not play its canonical role in double strand break repair 
in pluripotent cells (Adams et al., 2010a). This finding has 
been supported by other labs (see (Nagaria et al., 2013) for 
review). 
 
The purpose of this study is to clarify what role ATM plays in 
hESCs. A previous report demonstrated that ATM is activated in 
response to DNA damage in hESCs, and that cells arrest in G2 
(Momcilović et al., 2009). These researchers then went on to 
show, using the ATM specific inhibitor KU-55933, that this 
arrest could be abrogated. However, Momcilovic et al drew these 
conclusions using an immense dose of KU-55933 (100 μM, 10x the 
concentration normally used), a dose that could conceivably 
affect several other proteins involved in the DNA damage 
response. 
 
Herein, we will investigate the role of ATM in cell cycle 
control using the next-generation ATM inhibitor, KU-60019. We 
have demonstrated KU-60019 to be a highly potent, highly 
specific inhibitor of ATM (Golding et al., 2009). We 
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successfully demonstrate that, in hESCs, ATM is activated in 
response to DNA damage as well as the inhibition of 
decatenation. Both of these insults cause a G2/M arrest, and 
this arrest is abrogated by the inhibition of ATM, supporting 
the hypothesis that ATM mediates the G2/M checkpoint. 
Additionally, we show, using live cell imaging, that inhibiting 
ATM significantly increases the time it takes for cells to 
complete mitosis. When decatenation is inhibited concurrently 
with ATM, cells will enter mitosis and fail to separate, 
essentially “giving up” and re-entering the cell cycle with 
double the normal amount of DNA. Following up on this finding, 
we show that prolonged culture under ATM inhibition causes an 
increase in DNA content, and that wash out and culture of cells 
in normal media begins to reverse this effect.  
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Materials and Methods 
 
Antibodies, reagents, and irradiation: 
Antibodies used were anti-p-ATM (1:1000) (Cell Signaling), -ATM 
(1:1000) (GeneTex, Inc.), -DNA-PK (1:1000) (BD Pharmingen), -p-
Histone H3 (1:500) (Cell Signaling Technologies), -CREST (1:75) 
(Fitzgerald Industries), and -Cyclin A (1:50) (Santa Cruz 
Biotechnologies). KU-60019 (provided by KuDOS Pharmaceuticals, 
Inc.) was dissolved in DMSO and used at a concentration of 3 μM. 
ICRF-193 (Enzo Life Sciences) was dissolved in DMSO and used at 
a concentration of 10 μM. Colcemid (Sigma-Aldrich) and 
nocodazole (Sigma-Aldrich) were dissolved in DMSO and used at 
concentrations of 100 ng and 100 nM, respectively. Irradiations 
were performed using a MDS Nordion Gammacell 40 research 
irradiator with a Cs-137 source delivering an approximate dose 
of 1.05 Gy/min. 
 
Cell culture: 
The human ESCs BG01V (ATCC, Rockville, MD), H9 (Thomson et al., 
1998), and H9-(v)1 (Werbowetski-Ogilvie et al., 2009) were 
cultured on a feeder-free  system using a Matrigel™ (BD 
Biosciences) basement membrane substrate and mTeSR™ (STEMCELL 
Technologies) or Stemline™ (Sigma-Aldrich) media. Matrigel™ 
coated dishes were created using WiCell™ protocols. The media 
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was changed daily and cells were passaged with Dispase™ 
(STEMCELL Technologies) at least once every five days. 
Experiments were performed 24-48 hours after passaging. 
 
Western blotting: 
Western blotting was performed as previously described (Adams et 
al., 2010a) with additional modifications. Cells were lysed in 
RIPA buffer supplemented with HALT™ protease and phosphatase 
inhibitors (Sigma-Aldrich). Proteins were separated on 
Criterion™ TGX gels (Bio-Rad Laboratories) and transferred to 
PVDF membranes, which were exposed to primary antibodies at a 
1:1000 dilution. Protein bands were detected and quantified 
using infrared-emitting conjugated secondary antibodies, either 
anti-rabbit DyeLight 800 (Rockland Immunochemicals, 
Gilbertsville PA) or anti-mouse Alexa 680 (Invitrogen) using the 
Odyssey infrared imaging system from Li-Cor Biosciences 
(Lincoln, NE). Densitometry was performed using ImageJ or Image 
Studio v2.0. 
 
Metaphase spreads and pseudomitotic index: 
Acquisition of metaphase spreads was accomplished as previously 
described (Campos et al., 2009). Cells and culture media were 
collected and centrifuged. The resulting pellet was resuspended 
in a hypotonic potassium chloride solution. The preparation was 
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fixed in a freshly made 3:1 methanol:acetic acid solution and 
dropped onto glass slides. The slides were dried over a steam 
bath and stained with Giemsa (Sigma-Aldrich). They were then 
imaged using the Ariol automated image analysis system 
(Molecular Devices LTD). Nuclei and metaphase spreads were 
counted using ImageJ. The percentage of entangled chromosomes 
(“pseudomitoses”) in ICRF-193 cells were divided by the 
percentage of metaphase spreads in cells treated with colcemid 
alone, giving the pseudomitotic index (Damelin et al., 2005). 
 
Flow cytometry: 
Cells were fixed in 100% methanol, permeabilized in 1% Triton X-
100/casein, and incubated with anti–phospho-Histone H3 antibody 
at 1:500 dilution for 1 h 30 min at room temperature. Cells were 
washed in PBS and incubated with goat anti-rabbit Alexa Fluor 
488 at 1:500 dilution for 45 min at room temperature. Cell cycle 
distribution was analyzed by propidium iodide staining (5 Ag/mL, 
0.1% Triton X-100/PBS). Flow cytometry was done on a BD 
Biosciences FACS Canto flow cytometer at the VCU Flow Cytometry 
Core Facility. Data was analyzed using the FACSDiva software. 
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Confocal imaging: 
Confocal imaging was performed as described previously (Adams et 
al., 2010a) with additional modifications. Cells were grown on 
Lab-Tek (Naperville, IL) glass slides coated with Matrigel. 
After treatment, cells were fixed with 3% paraformaldehyde, 
permeabilized with 0.5% Triton-X 100 in phosphate-buffered 
saline (PBS) and blocked with casein/3% goat serum. Primary 
antibodies were incubated overnight at 4 degrees, with rotation 
(using the concentrations listed previously). The next day, 
samples were incubated for 2.5 hours at room temperature with a 
secondary antibodies solution (Alexa 488 goat anti-rabbit or 
goat anti-mouse 546 Fab fragment (Invitrogen)) at a 1:400 
dilution. The nuclei were counterstained with DAPI (1 mg/ml). 
Cells were imaged using a Zeiss LSM 710 Meta imaging system in 
the VCU Microscopy Facility and analyzed using the Volocity 
software from PerkinElmer. 
 
Live-cell imaging:  
Live-cell imaging was performed as described in (Beckta et al., 
2012), using a Zeiss Cell Observer SD spinning disk confocal 
microscope. BG01V hESCs were transduced with a Histone H2B-
mCherry construct to visualize chromatin. Glass-bottom dishes 
were coated with Matrigel and cells were passaged onto these 
dishes 24-48 hours prior to recording. Cells were kept on an 
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incubated stage at 37°C and 5% CO2. Videos were analyzed using 
PerkinElmer’s Volocity software. 
 
Statistics: 
ANOVA, t-tests, and linear regression were performed using 
GraphPad Prism 3.0 (GraphPad Software, Inc). P values are 
indicated as *, 0.05, **, 0.01, and ***, 0.001. 
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Results 
 
ATM is present and active in hESCs. KU-60019 inhibits ATM 
activation in response to irradiation. 
 
Studies were conducted using the BG01V, H9, and H9 variant H9-
(v)1 hESC lines. Our lab has previously developed optimal 
conditions for the growth and propagation of hESCs (Adams et 
al., 2010a). Notably, we employ a basement membrane substrate to 
grow the hESCs, thus avoiding the use of MEF feeder layers and 
ensuring our cultures are free of xenobiotic contamination. 
Successful maintenance of the pluripotent state was verified by 
immunocytochemistry (ICC) for SSEA-4 (Figure 3.1). Western 
blotting was used to confirm that ATM was present and active in 
the hESCs, and that KU-60019, a drug which we have shown to be a 
highly effective inhibitor of ATM (Golding et al., 2009), 
functioned as expected at a concentration which we have 
determined only inhibits ATM. hESCs were exposed to 3 μM of KU-
60019, 2 Gy of radiation, or both KU-60019 and radiation. KU-
60019 was added 30 minutes before irradiation; cells were 
harvested 30 minutes after irradiation. Predictably, irradiation 
catalyzed the activation of ATM, and KU-60019 abrogated this 
effect (Figure 3.2). 
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Catalytic inhibition of Topoisomerase II activates ATM and 
accumulates cells in G2. KU-60019 inhibits ATM activation. 
 
During and after DNA replication, daughter chromatids contain 
areas of entanglement, or catenations. The ability of cells to 
resolve these entanglements is dependent upon topoisomerase II 
(topoII), which unravels the chromosomes via the same method it 
uses to relieve helical stress. In order to inhibit 
decatenation, we used the bisdioxopiperazine ICRF-193, a topoII 
catalytic inhibitor that does not cause DNA double strand breaks 
(Roca et al., 1994). Treatment with 10 μM of ICRF-193 for four 
hours caused significant ATM activation in S and G2 phase, 
though this activation occurred most significantly in G2 (Figure 
3). Exposure to KU-60019 in addition to ICRF-193 inhibited ATM 
activation (Figure 3.3). Cell cycle analysis revealed that in 
contrast to control or KU-treated cells, exposure to ICRF-193 
accumulated cells in G2 (Figure 3.4). These data indicate that 
after catalytic inhibition of topoisomerase II, hESCs activate 
ATM and enact the decatenation checkpoint.  
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Inhibition of ATM abrogates both the DNA damage and the 
decatenation checkpoints. 
 
The purpose of a G2 arrest is to prevent damaged cells from 
entering mitosis and passing on any deleterious genetic lesions 
to daughter cells. Thus, we determined the mitotic accumulation 
of hESCs after inhibition of decatenation to assess the 
effectiveness of the G2/M checkpoint. To ensure that we are 
looking exclusively at G2/M entry (and prevent any confounding 
results from differences in mitotic exit) we used colcemid, a 
microtubule poison that prevents mitotic exit (Bower et al., 
2010b). H9, H9-v1, and BG01V cells were treated for four hours 
with KU-60019, ICRF-193, or both KU-60019 and ICRF-193, and 
analyzed for positive staining of phospho-Histone H3 (an 
established marker of mitosis). Catalytic inhibition of TopoII 
significantly reduced mitotic accumulation; inhibition of ATM 
abolished this effect (Figures 3.5A, 3.5B, 3.5C). This result 
was also observed in hESCs treated with irradiation (Figure 
3.6A). 
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Inhibition of ATM abrogates the decatenation checkpoint and 
increases the mitotic entry rate. 
 
In order to calculate the mitotic entry rate of hESCs, H9 cells 
were exposed to ICRF-193 and/or KU-60019 for 2, 4, and 6 hours. 
ICRF-193 reduced the mitotic accumulation and rate of 
accumulation, decreasing the slope (from colcemid-only control) 
by 2.7 fold. When KU-60019 was added simultaneously with ICRF-
193, mitotic accumulation recovered, and the mitotic entry rate 
rose dramatically, increasing the slope nearly 2 fold (Figure 
3.7A). BG01V hESCs were exposed to the same treatments. Similar 
to the H9 cells, ICRF-193 reduced the mitotic accumulation and 
rate of accumulation (decreasing the slope 1.5 fold). When KU-
60019 was added simultaneously with ICRF-193, mitotic 
accumulation recovered, and the mitotic entry rate increased 
(increasing the slope 1.3 fold) (Figure 3.7B). 
 
Inhibition of ATM significantly decreases the efficiency of the 
decatenation checkpoint. 
 
To determine the efficiency of the checkpoint, we used metaphase 
spreads and calculated the pseudomitotic index, which is defined 
as “the frequency of pseudomitosis in ICRF-193-treated cells 
divided by the frequency of mitosis in mock-treated cells”  
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(Damelin et al., 2005).  “Pseudomitosis” refers to the 
appearance of chromosomes in mitotic spreads that have a 
bizarre, entangled morphology (Figure 3.8A). As seen in Figure 
3.8B, we found that BG01V hES cells have a baseline 
pseudomitotic index of ~30%. Inhibiting ATM significantly 
increased the pseudomitotic index 4-fold. In addition to 
demonstrating ATM’s importance in preventing cells from entering 
mitosis with tangled DNA, these results also support a previous 
study’s finding that pluripotent cells have a deficient 
decatenation checkpoint, as fully differentiated cells have a 
pseudomitotic index of ~1% (Damelin et al., 2005). 
 
Inhibition of ATM increases the time it takes to complete the 
stages of mitosis. 
 
As described in (Beckta et al., 2012), live-cell imaging studies 
were conducted on BG01V cells transduced with a Histone H2B-
mCherry construct. The Wahl lab has demonstrated that the H2B-
fluorescent fusion protein is incorporated into nucleosomes, 
does not affect cell cycle progression, and permits high 
resolution confocal imaging of interphase chromatin and mitotic 
chromosomes (Kanda et al., 1998).  
 
As our previous data demonstrates, ATM is necessary for cells to  
98 
 
  
99 
 
detect genetic abnormalities and prevent further cell cycle 
progression. We were therefore interested in investigating if 
inhibiting ATM prolonged the time of mitosis, with the rationale 
being that catenations/DNA damage would escape notice and cells 
would erroneously enter mitosis, “discovering” and attempting to 
resolve any genomic lesions while concurrently attempting to 
divide. As hypothesized, inhibition of ATM prolonged the time of 
mitosis. Addition of KU-60019 prolonged the prometaphase-to-
metaphase time by 28% (Figure 3.9A), the metaphase-to-chromatin 
decondensation time by 17% (Figure 3.9B), and the overall time 
of mitosis by 21% (Figure 3.9C). This data demonstrates that 
without functional ATM, cells are still able to complete 
mitosis, but the increased time it takes them to do so indicates 
that they are either attempting to resolve undetected glitches 
in their DNA or proceeding to divide with these genetic flaws 
intact. 
 
Inhibition of ATM causes tetraploid cell formation.  
 
Our previous data has demonstrated the inhibiting both TopoII 
and ATM allows catenated cells to enter mitosis. However, the 
techniques used did not allow us to discern if the cells 
remained viable. BG01V Histone H2B-mCherry cells were exposed to 
various treatments and monitored via live-cell imaging for  
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several hours. Under normal conditions, BG01V cells enter 
mitosis at a rate of approximately 3.5% per hour (as calculated 
by cells demonstrating prometaphase morphology divided by the 
total number of cells observed). Addition of ICRF-193 reduces 
the mitotic entry rate by ~3 fold (Figure 3.10A); supporting our 
previous results which indicate that while exposure to ICRF-193 
activates the decatenation checkpoint, this activation does not 
result in complete arrest. While the majority of cells remained 
in interphase, approximately 40% of the ICRF-193 treated cells 
that entered mitosis “gave up” at metaphase, decondensed their 
chromatin, and re-entered the cell cycle as newly minted 
tetraploid cells (also known as “endoreduplication”) (Figure 
3.10B). Cells were also exposed to both ICRF-193 and KU-60019, 
which rescued mitotic entry to near control levels (Figure 
3.10A). As was seen in the ICRF-193-only treated cells, 
concurrent inhibition of ATM and decatenation caused nearly 40% 
of mitotic cells to become tetraploid, however, the dramatically 
increased mitotic entry rate meant that many more cells wound up 
with a gain of DNA (Figure 10B). This data clearly demonstrates 
the critical role ATM plays in preventing cells with gross 
changes to their DNA content from dividing. 
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Inhibition of ATM causes aneuploidy. 
 
The previous data indicated that cells with enormous genomic 
errors could survive and propagate if ATM was inhibited. We were 
therefore interested in uncovering what changes prolonged 
pharmacologic inhibition of ATM would cause in hESCs. H9 cells 
were exposed to KU-60019 for 24 hours, fixed immediately, and 
stained for CREST and Cyclin A. Kinetochores (revealed via CREST 
staining) were compared between control and KU-60019 treated 
cells. Cyclin A positive cells (representing S and G2 phase 
cells) were excluded in the analysis. 24 hours of ATM inhibition 
significantly increased the number of kinetochores counted per 
cell (Figure 3.11A), indicating that these cells gained DNA. 
Additionally, H9 cells were exposed to KU-60019 for 24 hours, 
then media was replaced and cells were allowed to grow for 24 
hours with no treatment, after which time the cells were fixed 
and stained with CREST and Cyclin A. While there was still a 
significant increase in the number of kinetochores per cell 
after ATM inhibition, the 24 hour washout period allowed cells 
to trend back to control levels (Figure 3.11B), suggesting that 
once ATM inhibition is relieved aneuploid cells are removed from 
the population (either via apoptosis or necrosis). 
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Chapter Summary 
 
Crucial to the development of therapeutics based on hESCs is an 
understanding of how they maintain genomic stability. Previous 
work in our lab has shown that while ATM is present and active 
in hESCs, it is not performing its canonical role in the DNA 
damage response. However, ATM is a key part of innumerable 
cellular signaling pathways that are important in the 
maintenance of genomic integrity. In order to elucidate ATM’s 
role in hESCs, we turned our attention to the G2/M decatenation 
and DNA damage checkpoints. Our current understanding of hESC 
cell cycle regulation suggests that these cells spend a very 
short time in G1 and lack a stringent G1/S checkpoint. This 
makes the enforcement of a G2/M checkpoint tremendously critical 
in hESCs. In this chapter, I have demonstrated that ATM is 
crucial for enacting the G2/M checkpoint(s) and preventing the 
generation of aneuploid cells. 
 
The data presented here shows that catalytic inhibition of 
TopoII activates ATM and causes cells to arrest in G2. While 
there is disparity in the literature, the activation of ATM in 
response to decatenation inhibition is consistent with other 
reports. Our studies used the highly effective ATM inhibitor, 
KU-60019. Our lab has previously shown KU-60019 to be 
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significantly more effective than KU-55933, the drug used in the 
only other study examining ATM’s role in hESC G2/M arrest 
(Momcilović et al., 2009). As seen in Figures 2 and 3, KU-60019 
is able to block the activation of ATM in hESCs at a dose of 3 
μM. However, there appears to be residual levels of p-ATM still 
present even after KU treatment. This is a phenomenon we have 
encountered before, and it has been shown that p-S1981 ATM 
antibody we use has the capacity to recognize multiple 
substrates (Matsuoka et al., 2007a). The background levels 
represent other activated members of the DNA damage response, 
either due to the ICRF-193 treatment or other cellular 
activities. 
 
We turned to live-cell imaging to record what is happening with 
ATM inhibition on a cell-by-cell basis. A previous report has 
shown that certain stages of mitosis were prolonged in MEFs with 
both ATM and p21 knocked out (Shen et al., 2005). This is of 
interest to our studies, as hESCs have low levels of p21 (see 
Chapter 1), so the results obtained with the use of an ATM 
inhibitor in a p21-negative background should be similar. 
However, these generalizations are hard to make. First, as with 
the other reports investigating ATM’s role in cell cycle 
regulation, there are significant species and lineage 
differences between stem cell populations. MEFs are both non-
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human and lack pluripotency. Additionally, use of cells with 
permanently knocked out proteins can encourage the cell to adapt 
and use other proteins/pathways. Here, we show for the first 
time that transient inhibition of ATM in hESCs is enough to 
significantly perturb the progression through mitosis. We 
hypothesize that this is potentially due to two reasons: first, 
ATM inhibition renders the cell unable to sense genomic insults 
and resolve them before entering mitosis. The cell must then 
deal with these issues as they interfere with the process of 
mitosis. Second, a recent manuscript has been published showing 
that ATM is important for the progression through mitosis via 
its signaling activity at the spindle assembly checkpoint (Yang 
et al., 2011). While this study was not done in pluripotent 
cells, ATM could potentially be playing a similar role in hESCs, 
causing an increase in the time of mitosis. 
 
Finally, we demonstrate that inhibiting ATM for as little as 24 
hours causes a significant increase in kinetochore staining, 
indicating a gain of DNA content. When cells were allowed to 
have a 24-hour washout period, kinetochore staining was still 
significantly increased, but trending back towards control 
levels. This suggests that the aneuploid cells, once ATM 
inhibition was released, undergo some type of cell death. Of 
note, the control groups only averaged around 19 kinetochores 
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per cell, instead of the expected 46. This is likely to be 
caused by the spatial relationships of the kinetochores in the 
nucleus. If CREST antigens are too close together (either in the 
X/Y or Z planes) then these foci will merge together and appear 
as one, larger foci. It would be virtually impossible to tease 
these groupings out using confocal imaging. Future studies using 
assays such as fluorescent in situ hybridization (FISH) could be 
employed to obtain a more accurate measurement of changes in DNA 
content.  
 
In summary, the experiments presented in this chapter have shown 
that ATM is important for G2/M cell cycle arrest, either due to 
DNA damage or inhibition of decatenation, in hESCs. At the same 
time, these experiments show that hESCs have a relatively weak 
decatenation checkpoint. Live-cell imaging studies have revealed 
that inhibition of ATM allows cells with substantially tangled 
DNA to attempt mitosis, and, when that attempt fails, to resume 
cycling as tetraploid cells. Importantly, experimental results 
have directly demonstrated that prolonged inhibition of ATM 
causes aneuploidy, and release from ATM inhibition reduces this 
effect. Taken together, these observations establish the 
importance of ATM in maintaining the genomic stability of hESCs. 
  
109 
 
Chapter 4:  
ATM, BRCA1, and Aurora A: How to 
Arrest a Cell 
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Introduction 
 
The mechanisms by which ATM could enact a G2/M arrest are 
numerous. A large-scale substrate analysis has identified more 
than 700 possible (and confirmed) targets of ATM (Matsuoka et 
al., 2007b), and, as is the case when studying globally-acting 
proteins, many of these targets play some sort of role in cell 
cycle regulation. Some of the early research into the 
decatenation checkpoint found evidence that the protein Plk1 
(polo-like kinase 1) is involved in checkpoint activation (Luo 
et al., 2009), and other studies have found that Plk1 is 
regulated by ATM in response to DNA damage (see (van Vugt et 
al., 2001), for example). Additionally, as Plk1 is regulated 
upstream by Aurora A, we decided to start the search for a 
mechanism in the Aurora A/Plk1 signaling pathway. 
 
Through exploring the literature for possible intersections 
between ATM and G2/M regulation pathways, we uncovered a little-
studied interaction between BRCA1 (a well-described target of 
ATM) and Aurora A. In 2004, a group working out of the Mt. Sinai 
School of Medicine published a report in which they present 
evidence showing that Aurora A binds to and phosphorylates 
BRCA1, and that this interaction is important for promoting the 
G2/M transition (Ouchi et al., 2004). Importantly, they showed 
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that Aurora A binds to BRCA1 in the amino acid region 1314-1863, 
which spans the SQ cluster domain where ATM exerts its kinase 
activity. By creating a mutant version of BRCA1 that was non-
phosphorylatable by Aurora A (S308N mutation), Ouchi and 
colleagues found that these cells were unable to enter mitosis, 
indicating that this small post translational modification of 
BRCA1 had major cell cycle consequences. 
 
Subsequent studies from the Parvin laboratory found that the 
phosphorylation of BRCA1 by Aurora A inhibited BRCA1’s E3 
ubiquitin ligase activity (Sankaran et al., 2005). BRCA1 
functions at centrosomes to 1) prevent centrosome amplification 
and 2) prevent microtubule nucleation. This second function, the 
inhibition of microtubule nucleation, is a conundrum. BRCA1 
localization to the centrosomes peaks during M phase, when 
microtubule nucleation activity is highest (Sankaran et al., 
2005). How is this seemingly contradictory information 
rectified? Sankaran et al found that Aurora A, by binding to and 
phosphorylating BRCA1, inhibits the ubiquitin-mediated 
inhibition, thus allowing appropriate formation of microtubules 
(Sankaran et al., 2005). It appears likely that BRCA1 targets 
centrosomes initially during S phase to prevent over-
amplification, and remains there in M phase, phosphorylated and 
inactive, except in the case of DNA damage. An independent 
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laboratory found that functional BRCA1 and Aurora A was 
necessary to prevent centrosome over-amplification after DNA 
damage (Brodie and Henderson, 2012). These studies suggest that 
BRCA1 remains localized to centrosomes as a fail-safe in the 
event that DNA damage is experienced and cycling needs to be 
halted.  
 
As activated ATM phosphorylates BRCA1 at several serine residues 
in the amino acid region in which Aurora A binds, and Aurora A 
binding/phosphorylation is necessary to inhibit BRCA1’s 
inhibition of microtubules (allowing the transition into 
mitosis), we hypothesize that ATM’s phosphorylation of BRCA1 
disrupts Aurora A binding. This disruption means that BRCA1 
continues to inhibit microtubules, and provides one plausible 
mechanism by which ATM activation turns on the G2/M checkpoint 
in response to DNA damage and/or tangled chromosomes.  
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Materials and Methods 
 
Antibodies, reagents, and irradiation: 
Antibodies used were anti-Aurora A (1:1000 WB, 1:500 ICC) (Cell 
Signaling Technologies), -p-Aurora A (1:1000 WB, 1:500 ICC) 
(Cell Signaling Technologies), -BRCA1 (Ab-1, Ab-4) (1:1000 WB, 
1:100 ICC) (Calbiochem), BRCA1 (C-20) (2 μg IP) (Santa Cruz 
Biotechnologies), –p-S1423-BRCA1 (1:1000 WB, 1:500 ICC) (Santa 
Cruz Biotechnologies), and –p-S308-BRCA1 (1:1000 WB) (kindly 
provided by Toru Ouchi). KU-60019 (provided by KuDOS 
Pharmaceuticals, Inc.) was dissolved in DMSO and used at a 
concentration of 3 μM. Nocodazole (Sigma-Aldrich) was dissolved 
in DMSO and used at a concentration of 100 nM. Irradiations were 
performed using a MDS Nordion Gammacell 40 research irradiator 
with a Cs-137 source delivering an approximate dose of 1.05 
Gy/min. 
 
Cell culture: 
The hESCs BG01V (ATCC, Rockville, MD) and H9 (Thomson et al., 
1998) were maintained as described in Chapter 3. Experiments 
were performed 24-48 hours after passaging, except in the case 
of immunoprecipitation reactions, where experiments were 
performed once cells became nearly confluent in a 10cm dish 
114 
 
(totaling 0.75 - 1 milligrams of protein). 
 
Western blotting: 
Western blotting was performed as described in Chapter 3. 
 
Confocal imaging: 
Confocal imaging was performed as described in Chapter 3. For 
co-localization experiments depicting cells in prometaphase, 
hESCs were fixed and assayed after 4 hours of nocodazole 
treatment. hESCs assayed for mitotic index were also fixed after 
4 hours of nocodazole treatment. 
 
Transfection:  
Generation of wild-type BRCA1 plasmid: 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 wild-type was generated as 
described in (Dever et al., 2011). 
Generation of 4P BRCA1 mutant plasmid:  
First, plasmid pcDNA3 (BssHII)-HA-3XFLAG-BRCA1 S1387/1423A was 
generated from plasmid pcDNA3-HA-BRCA1 S1387/1423A (kindly 
provided by Bo Xu) by swapping the BamHI XhoI fragments with 
pcDNA3 (BssHII)-HA-3XFLAG-BRCA1 wild-type.  The 
S1387/1423/1457/1524A quadruple mutant was then generated from 
plasmid pcDNA3(BssHII)-HA-3XFLAG-BRCA1 S1387/1423A by sequential 
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rounds of QuikChange site-directed mutagenesis (Stratagene) 
using primers GCAGTATTAACTGCACAGAAAAGTAGTG and 
CACTACTTTTCTGTGCAGTTAATACTGC to create the S1457A mutation and 
primers GAATAGAAACTACCCAGCTCAAGAGGAGCTC and 
GAGCTCCTCTTGAGCTGGGTAGTTTCTATTC to create the S1524A mutation.  
 
Transfection procedure:  
Transfections were performed using Qiagen’s SuperFect and their 
recommended protocol. In brief, 10 μg of plasmid DNA (in 5 μL of 
water) was complexed with 10 μL of SuperFect. DNA/SuperFect 
complex was incubated with cells for 3 hours, after which the 
cells were washed 1x in PBS. Assays were conducted ~48 hours 
after transfection.  
 
Immunoprecipitation and co-immunoprecipitation: 
Cells were lysed in a modified RIPA buffer (1% NP-40, 150 mM 
NaCl, 50 mM HEPES, HALT™ protease and phosphatase) or MPER 
buffer (Thermo Scientific Pierce). Protein levels were measured 
to be ~750 μg. For BRCA1 immunoprecipitation, 5 μg of BRCA1 C-20 
antibody was added to each lysate, and the samples were allowed 
to incubate overnight at 4°. For p-BRCA1/Aurora A co-
immunoprecipitation, 5 μg of p-S1423-BRCA1 was used. 50 μL of 
Dynabeads (Invitrogen) were added the following morning and 
incubated for an additional 2 hours at 4°. The samples were 
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washed three times in ice-cold PBS, mixed with Laemlli buffer + 
β-mercaptoethanol, and boiled for 10 minutes. The lysates were 
then loaded onto a Criterion™ TGX gel and run as earlier 
described. To minimize noise from the IgG heavy chain, blots 
were incubated with light chain specific secondary antibodies 
(Jackson Immuno) at 1:600 and developed on a GelDoc (Bio-Rad 
Laboratories) imaging system.  
 
λ-phosphatase assay: 
Lysates were immunoprecipitated as previously described using 
the BRCA1 C-20 antibody. Lambda Protein Phosphatase (New England 
BioLabs) was used per manufacturer’s protocols. In brief, 
samples were incubated with ~1,200 units of λ-phosphatase for 1 
hour at 30 °, after which time laemmli buffer was added and 
samples were boiled for 10 minutes. 
 
Statistics: 
T-test was performed using GraphPad Prism 3.0 (GraphPad 
Software, Inc). P value is indicated as ***, 0.001. 
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Results 
 
ATM phosphorylates BRCA1 in response to DNA damage.  
 
As discussed in Chapter 2, ATM directly phosphorylates BRCA1 in 
the SQ domain in response to DNA damage. While this has been 
demonstrated in multiple studies since it was first discovered, 
no one has examined if this phenomenon occurs in hESCs. First, 
hESCs were treated with or without KU-60019 for 30 minutes prior 
to exposure to 5 Gy IR. Cells were allowed to incubate for 1 
hour before lysates were harvested for western blot analysis. As 
seen in Figure 4.1A, there is a high basal level of p-S1423-
BRCA1 in control and KU-60019-alone treated cells. Treatment 
with IR caused a 1.6-fold increase in p-BRCA1 levels, while 
concurrent treatment with KU-60019 prevented this increase. 
These results indicate (in line with the literature) that ATM 
phosphorylates BRCA1 in response to DNA damage in hESCs.  
 
Unexpectedly, these results indicate that hESCs contain a high 
endogenous level of p-BRCA1, even in the absence of any overt 
DNA-damaging treatment. Additionally, inhibition of ATM, while 
preventing the increase in p-BRCA1 levels, does not do much to 
alleviate this phosphorylation (see Figure 4.1A, untreated vs. 
KU-60019 treated lanes). These results could indicate two  
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distinct possibilities: 1) the p-S1423-BRCA1 antibody used is 
recognizing un-phosphorylated BRCA1, or, 2) hESCs, for whatever 
reason, function with an unanticipatedly high amount of p-BRCA1. 
The original manuscripts describing ATM’s phosphorylation of 
BRCA1 used gel-shift assays to determine how these two proteins 
interact (in lieu of having p-BRCA1-specific antibodies). 
Therefore, to clarify which of the two possible events is 
occurring here, endogenous BRCA1 was immunoprecipitated from 
hESC lysates treated with or without IR and/or KU-60019. Samples 
were then run out on a 7.5% gel for an extended period of time 
to separate different molecular weight versions of BRCA1. As 
seen in Figure 4.1B, control and KU-60019-treated cells stain 
for two distinct versions of BRCA1. When treated with IR, a 
third species develops, which disappears with concurrent ATM 
inhibition. It appears that hESCs have three “versions” of 
BRCA1, with varying amounts of post-translational modifications. 
There appears to be a relatively constant amount of the highest-
mobility BRCA1 version throughout all groups. The middle-weight 
band varies based on treatment, remaining fairly similar between 
control and KU-60019-treated cells, while diminishing with 
exposure to IR. It seems that the third, most heavily modified 
band is generated using the middle-weight band as a substrate. 
While it is presumed that the ATM-mediated post-translation 
modification of BRCA1 is chiefly phosphorylation, this is not 
120 
 
guaranteed. Therefore, hESCs were treated with or without IR, 
harvested, and immunoprecipated for endogenous BRCA1. Extracts 
were then exposed to λ-phosphatase, a Mn2+-dependent protein 
phosphatase which removes phosphorylations from serine, 
threonine, and tyrosine residues. As seen in Figure 4.1C, 
exposure to IR induces the appearance of three different BRCA1 
species, while λ-phosphatase treatment reverses this effect. 
Collectively, these results indicate that BRCA1 is extensively 
phosphorylated by ATM in response to DNA damage, and ATM 
inhibition prevents this phosphorylation. However, it appears 
that at least one other kinase (possibly ATR (Gatei et al., 
2001)) is still acting extensively in BRCA1’s SQ cluster domain, 
regardless of treatment. Which protein is responsible and what 
purpose this continuous phosphorylation serves remains unclear.  
 
BRCA1 and Aurora A co-localize during mitosis. 
 
Previous reports have indicated that BRCA1 interacts with Aurora 
A, and that this interaction is important for the entry into 
mitosis (Ouchi et al., 2004). To investigate if this occurs in 
hESCs, cells were grown on chamber slides, fixed, and stained 
for BRCA1 and p-Aurora A. Figure 4.2A shows BRCA1 and Aurora A 
co-localize in prometaphase, while Figure 4.2B demonstrates this 
interaction in metaphase. This co-localization was not witnessed  
121 
 
  
122 
 
in any other phase of the cell cycle, in fact, little to no 
Aurora A staining (either total or phospho) was recorded outside 
of mitosis. This is likely because Aurora A is expressed at low 
levels during interphase, peaks at G2/M, and is degraded at the 
end of mitosis (Tanaka et al., 2002; Vader and Lens, 2008). 
 
Activation of ATM blocks the interaction of BRCA1 and Aurora A. 
Treatment with KU-60019 reverses this effect. 
 
Previous work has yielded data that shows Aurora A binding to 
the region of BRCA1 in which the SQ cluster domain resides, and 
that this binding is necessary for the S308-BRCA1 
phosphorylation which promotes the transition into mitosis 
(Ouchi et al., 2004). We hypothesized that activated ATM 
phosphorylates BRCA1’s SQ cluster domain and disrupts this 
interaction, and that this disruption is one mechanism by which 
ATM arrests cells at the G2/M border. However, repeated attempts 
at co-immunoprecipitating Aurora A with endogenous BRCA1 were 
unsuccessful, regardless of treatment (a similar amount of 
Aurora A always came down with BRCA1) (data not shown). Since 
hESCs seem to contain high levels of p-BRCA1 (Figure 4.1), we 
decided to use the p-S1423-BRCA1 antibody for both 
immunocytochemistry co-localization and western blot co-
immunoprecipitation experiments. Figure 4.3A shows p-BRCA1 co- 
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localizing with Aurora A in control and KU-60019 treated cells. 
In IR-treated cells, this interaction disappears, although most 
nuclei demonstrated p-BRCA1 foci (presumably indicating areas of 
DNA damage). When cells were irradiated under ATM inhibition, 
the BRCA1/Aurora A co-localization was restored. 
 
The same trend was seen with endogenous p-BRCA1 co-
immunoprecipitation experiments. As demonstrated in Figure 4.3B, 
a similar amount of Aurora A was immunoprecipitated along with 
p-BRCA1 in control and KU-60019-treated lysates (1x and 1.3x, 
respectively, when normalized for total amount of p-BRCA1). 
Treatment with 5 Gy IR dramatically reduced the amount of Aurora 
A pulled down, while treatment with both KU-60019 and IR 
restored the BRCA1/Aurora A interaction. Collectively, these 
results indicate that BRCA1 and Aurora-A interact in hESCs, and 
that ATM activation disrupts this relationship. 
 
IR decreases Aurora A-mediated phosphorylation of S308-BRCA1. 
Concurrent inhibition of ATM reverses this effect.  
 
The interaction between BRCA1 and Aurora A results in Aurora A 
phosphorylating BRCA1 at Serine 308, and this post-translation 
modification is important for mitotic entry regulation (Ouchi et 
al., 2004). This result has been independently validated and 
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experimental results have also shown that BRCA1 phosphorylation 
by Aurora A is important for BRCA1’s retention at centrosomes 
(Brodie and Henderson, 2012) as well as its regulation of 
mitotic microtubule nucleation (Sankaran et al., 2005). 
Therefore, it is likely that by disrupting the interaction of 
BRCA1 and Aurora A, ATM is preventing Aurora A from 
phosphorylating BRCA1. To test this hypothesis, we first 
immunoprecipitated endogenous BRCA1 from hESC lysates that were 
treated the same way as in previous experiments (with or without 
KU-60019 and/or 5 Gy IR). As shown in Figure 4.4, the DNA damage 
caused by IR drastically reduced the amount of p-S308-BRCA1. 
This effect was reversed by ATM inhibition, indicating that ATM 
activation not only disrupts the BRCA1/Aurora A interaction, it 
also prevents the BRCA1 serine phosphorylation that is important 
for mitotic regulation and entry. 
 
Expression of a non-phosphorylatable BRCA1 mutant mimics the 
ATM-inhibited phenotype. 
 
In order to corroborate the results obtained with the 
pharmacologic inhibition of ATM, we created a FLAG-tagged mutant 
version of BRCA1 in which four critical serine residues (targets 
of both ATM and ATR) are mutated to alanine (referred to as the 
“4P” mutant) (see Figure 4.5 for a schematic of the plasmids  
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used). If our hypothesis is correct, and the extensive 
phosphorylation of the SQ cluster of BRCA1 prevents the entry 
into mitosis, then cells transfected with the 4P mutant should 
display defects in cell cycle arrest. Both FLAG-tagged wild type 
(WT) BRCA1 and the 4P mutant were transfected into 293T cells to 
check for expression. Once it was confirmed that the plasmids 
translated and transcribed appropriately (Figure 4.6A), they 
were transfected into hESCs using SuperFect. In un-irradiated 
cells, the 4P-mutant cells had a higher (though not significant) 
mitotic index than the WT cells. However, after 5 Gy IR, 4P 
cells had a significantly higher mitotic index when compared to 
WT cells (an almost 4-fold increase) (Figure 4.6B). 
Interestingly, the 4P cells (both control and irradiated) 
demonstrated an obvious reduction in cell number, indicating the 
serine-to-alanine mutations were somewhat toxic to the cells. 
Presumably, the high basal levels of p-BRCA1 in hESCs somehow 
promotes survival, either through enhanced DNA repair, more 
efficient cell cycle checkpoints, or some combination of the 
two. 
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Chapter Summary 
 
While the experimental results presented in Chapter 3 clearly 
demonstrate that ATM regulates the entry into and the 
progression through mitosis in hESCs, the mechanism by which it 
exerts this control is unknown. As discussed earlier, it is well 
established that activated ATM phosphorylates BRCA1, and there 
have been several papers published which demonstrate that BRCA1 
plays a role in regulating the G2/M checkpoint. One pathway by 
which BRCA1 controls G2/M arrest is through its interaction with 
Aurora A. As Aurora A binds to and interacts with BRCA1 in the 
SQ cluster domain (the target of ATM’s kinase activity), we 
turned our attention to BRCA1 and Aurora A in order to clarify 
how ATM activation affects this relationship and the transition 
into mitosis. 
 
The data presented in Chapter 4 indicates that ATM activation 
increases the phosphorylation of BRCA1, an event that is blocked 
by the addition of our ATM inhibitor, KU-60019. Interestingly, 
there appears to be a relatively high level of p-BRCA1, 
regardless of ATM activation or inhibition. This steady amount 
of phosphorylation on other downstream ATM-targeted proteins has 
not been seen in our hands, though we have investigated this in 
the past (Adams et al., 2010a, 2010b). As it is extremely 
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important for hESCs to maintain their genetic integrity, perhaps 
a constitutively phosphorylated/activated BRCA1 enhances its 
ability to detect and repair potentially harmful lesions in the 
DNA. Additionally, the high basal level of phosphorylation could 
account for the relative “leakiness” of the G2/M checkpoint that 
was shown in Chapter 3. If the phosphorylation of BRCA1 is 
important for checkpoint activation, but there is already a high 
level of p-BRCA1, then maybe the additional phosphorylation 
brought on by DNA damage is only partially successfully in 
arresting the cell – a case of not being able to see the forest 
for the trees. 
 
We were able to see BRCA1 and Aurora A interacting in hESCs, 
though this was only witnessed during the early-to-mid phases of 
mitosis. The most interesting result of these experiments was 
the relative failure of the endogenous BRCA1/Aurora A co-
immunoprecipitation using the Santa Cruz C-20 BRCA1 antibody, 
arguably the most published, most successful BRCA1 antibody that 
is available. While BRCA1 could be routinely immunoprecipitated 
from hESC lysates, a constant, similar level of Aurora A co-
immunoprecipated with it, regardless of treatment. The fact that 
we were only able to tease out differences using the p-S1423-
BRCA1 antibody suggests several possibilities. First, based on 
the results obtained in Figure 4.1 A and B, there seems to be a 
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small population of un-phosphorylated BRCA1 in hESCs. Perhaps 
this population always interacts with Aurora A, regardless of 
other events occurring in the cell. Second, many papers have 
been published describing BRCA1 interacting with a wide variety 
of proteins. The C-20 antibody recognizes the C-terminus of BRCA 
– the region in which many proteins have been shown to bind.  It 
could be that, in hESCs, it is a simple case of too many 
partners interacting with BRCA1, preventing the antibody from 
recognizing its substrate. By using the p-S1423-BRCA1 antibody, 
we are trying to grasp on to a different “handle” of BRCA1 – one 
that is more successful. The fact that even after 5 Gy of IR 
there was still a small amount of Aurora A co-
immunoprecipitating with p-BRCA1, and a small level of p-S308-
BRCA1 detected, further corroborates the results presented in 
Chapter 3 which suggest that hESCs have a relatively weak G2/M 
checkpoint.  
 
As artificial modulation of ATM activity can prolong the stages 
of mitosis (described in Chapter 3) as well as the BRCA1/Aurora 
A interaction, perhaps the extra time measured is a result of 
abnormal microtubule nucleation instead of (or, in addition to) 
the cell “missing” DNA damage and letting the cycle continue. 
Without ATM becoming activated and blocking Aurora A from 
interacting with and phosphorylating BRCA1, BRCA1’s ubiquitin 
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ligase activity remains unregulated and appropriate numbers of 
microtubules are not formed in a reasonable amount of time. By 
preventing ATM from phosphorylating BRCA1, the cell builds 
excessive amounts of the mitotic architecture (even in the face 
of DNA damage), and while it can successfully traverse mitosis, 
it does not do so without significant setbacks. Additionally, 
BRCA1 functions to prevent abnormal centrosome amplification. 
The recorded aneuploidy that results from continuous ATM 
inhibition (Chapter 3) might well be a result of the cell’s 
failure to regulate BRCA1 and thus, more than two centrosomes 
per dividing cell are created, leading to multi-polar asters and 
the development of aneuploidy. 
 
Finally, seeing similar results with the 4P BRCA1 mutant 
transfected hESCs (as compared to the ATM-inhibited treated 
cells) is promising, though this method is not without its 
drawbacks. Chief among the issues raised by assaying cells in 
this manner is the fact that the hESCs used continue to express 
their own endogenous and fully phosphorylatable BRCA1. However, 
similar experiments are currently being conducted in BRCA1-null 
ovarian cancer cells, and our results in these cells (deficient 
cell cycle checkpoints and DNA repair) have generally replicated 
what we have seen in hESCs (Dever, Beckta et al, in 
preparation). 
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The data presented in this chapter provides one plausible 
mechanism by which ATM activation causes G2/M arrest. It is 
likely that, similar to their differentiated cousins, many 
different proteins and pathways contribute to cell cycle arrest 
in pluripotent cells. These other pathways remain open for 
future study. 
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Chapter 5:  
Conclusions 
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This work has demonstrated a clear role for the ATM kinase in 
human embryonic stem cells. ATM activates in response to both 
decatenation inhibition as well as irradiation-induced DNA 
damage, and this activation results in a G2/M arrest. Treatment 
of hESCs with a potent ATM-inhibitor, KU-60019, abrogates this 
arrest and allows cells to enter mitosis. Once past the G2/M 
checkpoint, ATM-inhibited cells experience a significantly 
prolonged mitosis, and concurrent inhibition of decatenation 
results in many instances of endoreduplication (where cells 
which have already copied their DNA enter mitosis, and, upon 
failing to separate appropriately, re-enter the cell cycle with 
a tetraploid amount of DNA). In line with this observation, 
continuous pharmacologic inhibition of ATM results in a 
significant increase in the average number of kinetochores per 
cell, indicating a stable gain of DNA content. 
 
The experiments presented here indicate that one possible 
mechanism by which ATM enacts a G2/M arrest is through 
disrupting the BRCA1/Aurora A interaction. BRCA1’s E3 ubiquitin 
ligase activity is important for regulating centrosome 
duplication (ensuring that only one centrosome copy is made per 
cell per cycle), as well as microtubule nucleation (the process 
by which microtubules are assembled from y-tubulin building 
blocks). When activated, ATM phosphorylates the SQ cluster 
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domain of BRCA1, the region in which Aurora A binds. This 
phosphorylation prevents Aurora A from interacting with BRCA1 
and, thus, prevents Aurora A from phosphorylating BRCA1 on S308, 
a modification which inhibits BRCA1’s inhibition of microtubule 
formation. Without this phosphorylation, an adequate number of 
microtubules cannot be constructed, preventing the cell from 
entering mitosis. Our proposed model of G2/M arrest in hESCs can 
be visualized in Figure 5.1. 
 
This mechanism lends itself well to some of the current theories 
of centrosomal participation in the DNA damage response and cell 
cycle checkpoint regulation. Like DNA, centrosomes are 
replicated once per cycle (in S phase), and this replication 
occurs in a semi-conservative manner. At the onset of mitosis, 
these two centrosomes separate, forming the iconic poles of the 
mitotic spindle (Löffler et al., 2006). One direct mechanism by 
which G2 arrest can be enacted is through the inhibition of this 
centrosomal separation. This response occurs in an ATM-dependent 
manner, and is mediated by a protein called Nek2 (Fletcher et 
al., 2004; Hinchcliffe et al., 2001), a kinase whose activity 
causes a loss of centriole cohension and leads to the 
centrosomal separation (Fry et al., 1998; Helps et al., 2000; 
Mayor et al., 2000). 
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Going beyond direct regulation as a means of arrest, several 
laboratories have put forward the hypothesis that centrosomes 
act as “command centers” for cell cycle control (Doxsey, 2001; 
Doxsey et al., 2005; Krämer et al., 2004). Many proteins 
involved in both the DNA damage response as well as cell cycle 
regulation have been found to localize to and interact with each 
other around centrosomes, in times of both stress and normal 
growth. It seems as if centrosomes act as some sort of 
spatiotemporal organizing center for growth control and stress 
response – a place where proteins can go to communicate and 
“make decisions” about whether or not to proceed in cycling (see 
(Löffler et al., 2006), for perspective). Additionally, 
centrosomes can act as a place for the cell to sequester 
proteins to allow cycling to continue even in the presence of 
damage. One study performed in mESCs found the key cell cycle 
checkpoint protein Chk2 was localized to and retained at 
centrosomes, preventing it from activating a G1/S checkpoint 
(Hong and Stambrook, 2004). Interestingly, this effect could be 
overcome through ectopic expression of Chk2, indicating that it 
was indeed the centrosomal sequestration that was abrogating the 
G1/S checkpoint. Our model of ATM regulating BRCA1/Aurora A as a 
means of checkpoint control fits in well with these previously 
published studies. 
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One potential issue with the experiments presented within this 
dissertation is our reliance on pharmacologic inhibition of ATM, 
as opposed to siRNA-mediated knockdown. However, we feel that 
the use of a drug as opposed to knockdown provides several key 
benefits for our studies. Most importantly, it avoids the major 
toxicity we experience when attempting to transfect siRNA into 
hESCs. While it is possible to strike a balance between 
efficiency and toxicity, this balance usually leaves us with 
inadequate cell numbers to derive any meaningful conclusions. We 
have also found that the stress of transfection can occasionally 
cause differentiation, further discouraging the use of siRNA. 
Additionally, as we have shown KU-60019 to be extremely 
effective even at nanomolar concentrations (Golding et al., 
2009), we can be reasonably sure that close to 100% of the cells 
are experiencing partial-to-complete inhibition of ATM, whereas 
it is highly unlikely that we could achieve such numbers with 
siRNA. Finally, the inhibitor can be used to quickly and 
transiently inhibit ATM. This avoids having to wait several days 
for the siRNA to exert its knockdown effect and allows us to 
conduct experiments in which the pharmacologic inhibition of ATM 
can be reversed (as was done in the kinetochore 
staining/aneuploidy assay in Chapter 3). 
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The use of a small molecule inhibitor of ATM versus protein 
knockdown in signaling studies does raise unique issues. In 
2010, Chris Bakkenist’s lab demonstrated that pharmacologic 
inhibition of ATM does not have the same phenotype as ATM 
protein knockdown or mutation (White et al., 2010). They 
speculate that this observation is the result of the kinase-
inhibited ATM still being able to localize to and function 
structurally at sites of DNA DSBs (Choi et al., 2010). It is 
likely that this non-functional version of ATM serves as a 
physical barrier, preventing any “back-up” proteins from coming 
in and picking up some of the slack for the malfunctioning ATM 
kinase. 
 
This could account for some of the differences seen in the 
literature between investigators examining ATM’s function using 
either knockdown or small molecule inhibitors. For example, a 
paper recently published in Cell demonstrated that Aurora B 
phosphorylates ATM at S1403 during mitosis (in the absence of 
DNA damage) (Yang et al., 2011). Interestingly, these 
researchers found that ATM-null or -mutant cells had a 
significantly shortened progression through mitosis when 
compared to wild-type cells. This is in direct contrast to the 
findings presented in Chapter 3, where pharmacologic inhibition 
of ATM in hESCs significantly prolonged the time of mitosis. 
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Similar to “blocking” events at DSBs, kinase-inhibited ATM could 
still localize to and interact with key mitosis-promoting 
proteins, preventing the correct sequence of events and 
prolonging the mitotic sequence. Perhaps conducting studies 
using both protein knockdown and small molecule inhibitors could 
grant us greater insight into the true functions of ATM and 
other proteins. 
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Future Directions 
 
As with any scientific investigation, the findings presented 
here only leave us with more unanswered questions. As such, 
there are still several ongoing experiments in this project that 
are not yet complete. The results of these studies will 
hopefully further clarify and reinforce that data which has 
already been presented. 
 
First, more work needs to be done with the BRCA1 wild-type and 
4-phospho-mutant constructs. If our hypothesis is correct, then 
the 4-phospho-mutant transfected cells should replicate most, if 
not all, of the ATM-inhibited cell cycle data. In parallel with 
this project, we have been using these BRCA1 constructs in a 
BRCA1-null ovarian cancer cell line to investigate similar 
endpoints (Dever & Beckta, in preparation). The data we have 
derived from these cancer cells have, so far, supported the data 
we have obtained in the hESCs. Most importantly, we need to 
demonstrate (using hESCs) that the 4-phospho-mutant BRCA1 can be 
immunoprecipitated, and that, when compared to wild-type BRCA1, 
more Aurora A is co-immunoprecipitated with it.  
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Second, we are in the process of creating an S308N-BRCA1 mutant 
construct to transfect into the stem cells. This version of 
BRCA1 should be unphosphorylatable by Aurora A, leaving BRCA1 
free to ubuiqitinate y-tubulin as much as possible. These S308N 
cells should phenocopy cells that have undergone ATM activation 
and arrest in G2/M. Unfortunately, it is likely that mimicking 
chronic ATM activation will lead to heavily arrested growth (or 
massive death), and it might be difficult to assay these cells 
appropriately. 
 
Finally, it would be interesting to repeat many of these studies 
(as well as our original studies examining the dynamic role of 
ATM and ATR in the DNA damage response) in human iPS cells. We 
have recently acquired well-characterized iPS cells from the 
Children’s Hospital of California (Stover et al., 2013), which 
have already been adapted to our xenobiotic-free culture 
protocols. These cells are an ideal way to translate our methods 
into a new pluripotent system within which we can continue to 
rigorously test our hypotheses.  
 
The work presented here continues to build upon the solid 
foundation of literature which has shown, time and time again, 
that our understanding of molecular signaling begins to break 
down when hESCs are involved. Pluripotent cells appear to be 
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governed by a different set of rules than their differentiated 
counterparts, and we still have much to learn. Clearly, a 
significant effort is needed to enhance our knowledge of the 
basic biology of these cells if we hope to employ them 
successfully in the clinic. 
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